<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2451,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/b10e2e1b81cfe142005c13f8c4941b8e'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/b10e2e1b81cfe142005c13f8c4941b8e'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1HKVDK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HKVDK003">Previous Result: <span>United States v. Parks, Case No. 1:09-cr...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1HL0D4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HL0D4003">Next Result: <span>United States v. Cornelius, 473 Fed. App...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion'>
United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion</div>
<div class='docId'>X1HKTUQ003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>United States v. Bader</div>
<div class='displayCitation'>2012 BL 109582</div>
<div class='displayCitation'>2012 BL 111342</div>
<div class='displayCitation'>678 F.3d 858</div>
<div class='displayCitation'>wkf10case:26033133</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HKTUQ003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="United States v. Bader" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1HKTUQ003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HKTUQ003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HKTUQ003" /><input id="title" name="title" type="hidden" value="United States v. Bader, 678 F.3d 858 (10th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="b10e2e1b81cfe142005c13f8c4941b8e" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HKTUQ003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fb%31%30e%32e%31b%38%31cfe%31%34%32%30%30%35c%31%33f%38c%34%39%34%31b%38e%2Fdocument%2FX%31HKTUQ%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/bcite/X1HKTUQ003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/bcite/X1HKTUQ003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/bcite/X1HKTUQ003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/related_content/X1HKTUQ003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1706107404291";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">678 F.3d 858</div>
<div class="cite" data-cite-type="DocketNumber">10-1263</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 111342</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Tenth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
UNITED STATES of America, Plaintiff-Appellee, v. Thomas BADER,
Defendant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-1263.
</center></p>
<p><center>
May 3, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Colorado.
</p></div>
<span CLASS="page_no" data-cite="678 f 3d 859" data-cite-type="PrimaryFederalReporter" data-cite-pageno="859" data-primary-citation="678 F.3d 858">[*859]</span> <div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 860" data-cite-type="PrimaryFederalReporter" data-cite-pageno="860" data-primary-citation="678 F.3d 858">[*860]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 861" data-cite-type="PrimaryFederalReporter" data-cite-pageno="861" data-primary-citation="678 F.3d 858">[*861]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 862" data-cite-type="PrimaryFederalReporter" data-cite-pageno="862" data-primary-citation="678 F.3d 858">[*862]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 863" data-cite-type="PrimaryFederalReporter" data-cite-pageno="863" data-primary-citation="678 F.3d 858">[*863]</span> 
</p></div>
</div>
<div id="para2" printdualcolumn="true"><p>
  Deborah A. Pearce, Law Offices of Deborah A. Pearce, New
Orleans, LA (Charles Torres and Joseph Machatton, Charles H.
Torres, PC, Denver, CO, with her on the briefs), for
Defendant-Appellant.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Jaime A. Pe&ntilde;a, Assistant United States Attorney
(John F. Walsh, United States Attorney, and Andrew A. Vogt, Assistant
United States Attorney, with him on the brief), Denver, CO, for
Plaintiff-Appellee.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before TYMKOVICH, BALDOCK, and HOLMES, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HOLMES, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Defendant-Appellant Thomas Bader appeals his convictions of
distribution of human growth hormone ("HGH"), conspiracy to
knowingly facilitate and knowingly facilitating the sale of HGH
brought into the United States contrary to law, and conspiracy
to possess with intent to distribute a controlled substance
(testosterone cypionate). He asks this court to reverse his
convictions or, at a minimum, to grant him a new trial. Mr.
Bader also challenges the district court's forfeiture order
requiring him to remit the $4.8 million in proceeds that he
allegedly derived from his unlawful activity. Exercising
jurisdiction pursuant to <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEIMU8003?jcsearch=28%20usc%201291&amp;summary=yes#jcite">28 U.S.C. &sect; 1291</a>, we affirm Mr.
Bader's convictions for distribution of HGH and conspiracy to
possess with intent to distribute testosterone cypionate, but
reverse based upon instructional error his convictions for
knowingly facilitating the sale of HGH imported into the United
States contrary to law, and conspiring to do so. Further, in
light of our reversals, we conclude that the forfeiture
judgment cannot rest on its current statutory basis, but we
leave to the district court in the first instance the task of
determining the precise amount (if any) of the forfeiture
judgment authorized by the remaining, upheld convictions. We
remand the case to the district court with instructions to
vacate the judgment and sentence and for further proceedings
consistent with this opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              <b>I. BACKGROUND</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader, a licensed pharmacist in the State of Colorado,
owned and operated College Pharmacy, a compounding pharmacy
located in Colorado Springs, Colorado. In the context of this
case, the precise definition of drug "compounding" remains in
dispute. Nevertheless, the parties agree that College Pharmacy
is involved in the process of purchasing, labeling,
repackaging, and distributing drugs &mdash; including HGH
&mdash; in finished <span CLASS="page_no" data-cite="2012 bl 111342 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> dosages for patient consumption.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In Spring 2004, Mr. Bader instructed Kevin Henry, a College
Pharmacy sales representative, to locate an economical source
of HGH for purchase and distribution
<span CLASS="page_no" data-cite="678 f 3d 864" data-cite-type="PrimaryFederalReporter" data-cite-pageno="864" data-primary-citation="678 F.3d 858">[*864]</span> 
Mr. Henry located three manufacturers &mdash; all of them
in China &mdash; and College Pharmacy began purchasing and
importing HGH from these sources. Upon learning of potential
contamination and potency issues with the HGH manufactured by
these Chinese suppliers, Mr. Bader asked Mr. Henry to find a
new HGH source. Pursuant to Mr. Bader's instructions, Mr. Henry
contacted Bradley Blum, a domestic representative for Chinese
HGH manufacturer Genescience, and College Pharmacy began to
order and import HGH in bulk quantities from the Genescience
facility in China.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Employees of College Pharmacy were then directed to repackage
the imported HGH into smaller vials for distribution. Pursuant
to College Pharmacy's repackaging protocol, employees copied
the relevant HGH drug-instruction guides from a Food and Drug
Administration ("FDA")-approved version of HGH known as Saizen
and included them with College Pharmacy's own HGH drug, which
they labeled and sold as Somatropin. If asked whether
Somatropin was FDA-approved, College Pharmacy employees were
instructed to explain that the FDA did not have jurisdiction in
China, and to reassure customers that the imported HGH was
manufactured in an FDA-approved Chinese facility. College
Pharmacy also issued several promotional letters and
advertisements which implied that Somatropin had been approved
by the FDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Between 2003 and 2007, Mr. Bader and his employees at College
Pharmacy also distributed testosterone cypionate, an anabolic
steroid, to individual body-builders and to body-building and
"anti-aging" clinics. Among College Pharmacy's top "clients"
was Peak Physique, a large anti-aging clinic that purchased HGH
and testosterone cypionate via purchase agreements that
required no prescription from a licensed physician. College
Pharmacy also promoted and sold the steroid, along with
Somatropin, at American Academy of Anti-Aging Medicine ("A4M")
conferences and trade shows, despite the fact that neither
"anti-aging" nor "body-building" is a medically necessary use
for these drugs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On September 9, 2008, the government filed a Second Superseding
Indictment in the District of Colorado charging Mr. Bader with
a total of forty-three counts involving: (1) conspiracy to
knowingly facilitate the sale of merchandise (HGH) brought into
the United States contrary to law, in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRNC003?jcsearch=18%20usc%20371&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>; (2) mail fraud, in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHSDU003?jcsearch=18%20usc%201341&amp;summary=yes#jcite">18 U.S.C. &sect; 1341</a>; (3) distribution of HGH, in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e); (4) knowingly facilitating the sale of merchandise
(HGH) brought into the United States contrary to law, in
violation of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>; and (5) conspiracy to possess
with intent to distribute a controlled substance (testosterone
cypionate), in violation of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976DK003?jcsearch=21%20usc%20846&amp;summary=yes#jcite">21 U.S.C. &sect;&sect; 846</a> and <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976D8003?jcsearch=21%20U.S.C.%20%20841&amp;summary=yes#jcite">841</a>. The
indictment also indicated that the government would seek a
forfeiture judgment in the amount of $4.8 million &mdash; the
estimated amount of proceeds obtained by Mr. Bader due to his
unlawful conduct &mdash; as well <span CLASS="page_no" data-cite="2012 bl 111342 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> as forfeiture of the College
Pharmacy building that allegedly had facilitated these crimes.
The government subsequently dismissed Mr. Bader's mail-fraud
charges, and Mr. Bader was tried on the remaining thirty-three
counts beginning on January 4, 2010.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On February 2, 2010, a jury convicted Mr. Bader on thirty-two
of the thirty-three counts of the indictment, acquitting him on
one count of receiving illegally imported goods
(Count Sixteen). The jury further found that Mr. Bader had obtained a
sum of $4.8 million in proceeds from his illegal activities,
and that the College Pharmacy building listed in the indictment
had facilitated the crimes charged. The district court entered
judgment on Mr. Bader's
<span CLASS="page_no" data-cite="678 f 3d 865" data-cite-type="PrimaryFederalReporter" data-cite-pageno="865" data-primary-citation="678 F.3d 858">[*865]</span> 
convictions and the jury's forfeiture verdict. Mr. Bader
then filed an array of post-trial motions, pursuant to which
the district court entered a judgment of acquittal on
twenty-three of the HGH distribution counts; they involved
prescriptions to minors, which had been validly issued by
licensed physicians. Mr. Bader was subsequently sentenced to a
below-Guidelines term of imprisonment of forty months and
exempted from any payment of a criminal fine, the court having
concluded that the forfeiture of $4.8 million and the
pharmacy-building constituted an adequate financial penalty.
This appeal followed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             <b>II. DISCUSSION</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader challenges on appeal each of his convictions and
attacks the district court's forfeiture order. More
specifically, Mr. Bader raises an array of arguments contesting
the legal propriety of the jury instructions and the
sufficiency of the evidence; alleges prosecutorial misconduct
and entrapment by estoppel; and asserts violations of his Sixth
Amendment rights and federal evidentiary rules. Mr. Bader asks
us to reverse his convictions or, in the alternative, to grant
him a new trial. We address below each of his challenges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>A. <i>Alleged Instructional Errors</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader alleges that the district court erroneously
instructed the jury in three ways: (1) by including an
"alternative prong on uncharged API [active pharmaceutical
ingredient] importation" when it issued instructions regarding
the charges of knowingly facilitating the sale of HGH imported
contrary to law and conspiring to do so, Aplt. Opening Br.
at 51; (2) "by telling the jury [that] all [of the] evidence about
compounding was irrelevant," <i></i><cite>id. at 47</cite>; and (3) by
refusing to instruct the jury on applicable state pharmacy laws
and his First Amendment right to advertise. The government
contends that any error in the court's "alternative prong"
instruction was harmless, that the district court was correct
to reject Mr. Bader's compounding definition, and that the
court properly refused to instruct the jury regarding state
pharmacy dispensing regulations and Mr. Bader's First Amendment
rights.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>1. "Finished" HGH versus API</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's first argument pertains to two of his convictions
&mdash; specifically, his convictions for knowingly
facilitating the sale of HGH imported into the United States
contrary to law and conspiring to do so (Counts Seventeen and
One of the <span CLASS="page_no" data-cite="2012 bl 111342 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> Second Superseding Indictment, respectively). These
convictions implicate <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>, which prohibits the
smuggling of illegal goods into the United States by providing,
in relevant part, that "[w]hoever fraudulently or knowingly
imports or brings into the United States, any merchandise
contrary to law, or receives . . . buys, [or] sells" such
merchandise, "knowing the same to have been imported or brought
into the United States contrary to law" shall be fined or
imprisoned for a maximum of twenty years. <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the present case, Mr. Bader was charged in Count One with
conspiring to knowingly facilitate the sale of HGH after
importation "knowing the same to have been imported into the
United States" contrary to several identified federal statutes:
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), which prohibits the introduction into
interstate commerce of a misbranded drug;
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f)(1), which relates to causing the introduction into
interstate commerce of a misbranded drug that fails to bear
adequate directions for use; <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(d)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(d), which
prohibits the introduction into interstate commerce of an
article that is in violation of
<span CLASS="page_no" data-cite="678 f 3d 866" data-cite-type="PrimaryFederalReporter" data-cite-pageno="866" data-primary-citation="678 F.3d 858">[*866]</span> 
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355&amp;summary=yes#jcite">section 355</a> of Title 21; and <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>, which
prohibits the introduction into interstate commerce of a "new
drug" without prior application to or approval from the FDA.
<i>See</i> Aplee. App., Vol. W, at 1027-28
(Second Superseding Indictment, returned Sept. 9, 2008). At bottom, the
charged conspiracy involved a scheme to import comparatively
cheap HGH from China, to sell that cheap HGH in order to reap
windfall proceeds, and to retain the proceeds. In Count
Seventeen, Mr. Bader was charged with a specific instance of
"knowingly facilitat[ing] the sale" of HGH, "knowing the same
to have been imported into the United States contrary to" the
federal laws cited above. <i>See </i><cite>id. at 1039</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to FDA documents, "finished drug products" must be
approved through an "effective new drug application" ("NDA")
before they can be legally imported.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> Aplt.App., Vol. I,
at 267 (Import Alert # 66-71, dated Jan. 23, 2007). Active
pharmaceutical ingredients ("API"), in contrast, may be legally
imported on a case-by-case basis if they are intended for use
in pharmacy compounding. <i></i><cite>Id. at 270-71</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government concedes that the district court significantly
limited the basis upon which the jury could convict Mr. Bader
under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a>, focusing upon the government's primary theory
that the HGH that Mr. Bader imported from China was a
"finished" drug product subject to FDA oversight and, because
Mr. Bader had failed to file an NDA, he had imported HGH
"contrary to" <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>'s ban on the importation of
"new drugs" that lack FDA approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the court later explained in its order partially granting
Mr. Bader's motion for judgment of acquittal, its instruction
on Count One &mdash; outlined in jury instruction number twenty
("Jury Instruction No. 20") &mdash; "[d]istilled to its
essence, . . . directed the jury to resolve the `imported
contrary to law* question by first determining whether the HGH
being imported was a `finished drug' or an `ingredient.'"
Aplee. App., Vol. IV, at 1258 (Op. &amp; Order Granting, in
Part, Mot. for J. of Acquittal and Den. Remaining Mots., filed
Apr. 29, 2010). The court further instructed that "[t]here is
no definition under the law for the term `finished <span CLASS="page_no" data-cite="2012 bl 111342 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> drug'" but
that "in determining whether the [HGH] was a finished drug,
[the jury could] consider whether it was in
<span CLASS="page_no" data-cite="678 f 3d 867" data-cite-type="PrimaryFederalReporter" data-cite-pageno="867" data-primary-citation="678 F.3d 858">[*867]</span> 
a finished dosage form; for example, a tablet, capsule, or
solution." Aplt. Trial Tr.App., Vol. VIII, at 2169
(Jury Instruction No. 20).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the event that the jury determined that the Chinese HGH was
in finished form, "they were instructed that a `finished drug"
must have NDA approval in order to be legally imported, and
because it was undisputed at trial that the HGH here did not
have such approval, a finding that the HGH was a `finished
drug' compelled the conclusion that it was `imported contrary
to law.'" Aplee. App., Vol. IV, at 1258-59; see Aplt.App., Vol.
VIII, Tr. at 2715-16. However, significantly, the district
court further instructed the jury, in the alternative, that if
the jury "[found] that the [HGH] was <i>not</i> a finished
drug but instead an active pharmaceutical ingredient," then it
still was authorized to find that the HGH was "imported
contrary to federal law <i>if it was manufactured by a foreign</i>
<i>entity that was not registered with the FDA</i>" Aplt. Trial
Tr.App., Vol. VIII, at 2170 (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Importantly, the district court incorporated the legal
standards concerning the contrary-to-law component of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a>, articulated in Count One's Jury Instruction 20, into the
instructions that would control the jury's finding as to Count
Seventeen. Specifically, the court stated: "For purposes of
determining whether the human growth hormone was imported into
the United States in a manner contrary to federal law, you
should use the same standards and instructions I gave you with
regard to that issue in Count 1." <i></i><cite>Id. at 2176</cite>.
Therefore, to the extent that a ground for reversal could be
demonstrated regarding Count One relating to a defect in Jury
Instruction 20's contrary-to-law standard, that ground for
reversal would also fatally undermine Mr. Bader's conviction as
to Count Seventeen because it employed the same standard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader contends that there is such a ground for reversal,
focusing on the final sentence of Jury Instruction 20, relating
to API importation. However, Mr. Bader did not specifically
object to this portion of Jury Instruction No. 20 at trial
&mdash; despite the fact that the court afforded him ample
opportunity to do so, <i>see </i><cite>id. at 2145</cite> (Jury Trial Tr.,
dated Jan. 28, 2010) ("Counsel, this is your second opportunity
to lodge any objections to the concluding jury instructions
reflected in the packet or to the verdict form."). At most, Mr.
Bader's counsel made a general "object[ion] to the [c]ourt's
instruction" &mdash; with no reference to which of the
enumerated instructions was put at issue in his objection
&mdash; and "reurge[d]" the court to adopt the defense's
compounding instruction. <i></i><cite>Id. at 2148</cite>. This falls far
short of Mr. Bader's obligation to lodge a timely and specific
objection. <i>See, e.g., Abuan v. Level 3 Commc'ns, Inc.</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XE42OB?jcsearch=353%20f%203d%201158&amp;summary=yes#jcite">353 F.3d 1158</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XE42OB?jcsearch=353%20f%203d%201158&amp;summary=yes#jcite">1172</a> (10th Cir. 2003) ("No party may assign as
error . . . the failure to give an instruction unless that
party objects thereto before the jury retires to consider its
verdict, stating distinctly the matter objected to and the
grounds of the objection." (quoting Fed.R.Civ.P. <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X144L40003?jcsearch=Fed.%20R.%20Civ.%20P.%2051&amp;summary=yes#jcite">51</a>) (internal
quotation marks omitted)); <i>Medlock v. Ortho Biotech,<span CLASS="page_no" data-cite="2012 bl 111342 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> </i>
<i>Inc.</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3M3MC?jcsearch=164%20f%203d%20545&amp;summary=yes#jcite">164 F.3d 545</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3M3MC?jcsearch=164%20f%203d%20545&amp;summary=yes#jcite">553</a> (10th Cir. 1999) ("Because the
purpose of [an] objection is to give the court an opportunity
to correct any mistake before the jury enters deliberations, an
excessively vague or general objection to the propriety of a
given instruction is insufficient to preserve the issue for
appeal." (citation omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We therefore review Mr. Bader's objection to Jury Instruction
No. 20 for plain error. <i>See, e.g., United States v.</i>
<i>Willis</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16AH6E003?jcsearch=476%20f%203d%201121&amp;summary=yes#jcite">476 F.3d 1121</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16AH6E003?jcsearch=476%20f%203d%201121&amp;summary=yes#jcite">1127</a> (10th Cir. 2007); <i>see</i>
<i>also</i> Aplee. App., Vol. IV, at 1261 ("In
<span CLASS="page_no" data-cite="678 f 3d 868" data-cite-type="PrimaryFederalReporter" data-cite-pageno="868" data-primary-citation="678 F.3d 858">[*868]</span> 
the absence of a specific objection, the [c]ourt need only
review the instruction for plain error. . . .")"Plain error
occurs when there is (i) error, (ii) that is plain, which (iii)
affects the defendant's substantial rights, and which (iv)
seriously affects the fairness, integrity, or public reputation
of judicial proceedings." <i>United States v.</i>
<i>Lopez-Medina</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1CIE16003?jcsearch=596%20f%203d%20716&amp;summary=yes#jcite">596 F.3d 716</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1CIE16003?jcsearch=596%20f%203d%20716&amp;summary=yes#jcite">738</a> (10th Cir. 2010) (quoting
<i>United States v. Ruiz-Terrazas</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16CD4K003?jcsearch=477%20f%203d%201196&amp;summary=yes#jcite">477 F.3d 1196</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16CD4K003?jcsearch=477%20f%203d%201196&amp;summary=yes#jcite">1199</a>
(10th Cir. 2007)) (internal quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In undertaking the threshold error inquiry, we must "determine
whether, as a whole, the instructions correctly state the
governing law and provide the jury with an ample understanding
of the issues and the applicable standards." <i>United States</i>
<i>v. Visinaiz</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X13JGGS003?jcsearch=428%20f%203d%201300&amp;summary=yes#jcite">428 F.3d 1300</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X13JGGS003?jcsearch=428%20f%203d%201300&amp;summary=yes#jcite">1308</a> (10th Cir. 2005) (quoting
<i>United States v. Smith</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12H5FO003?jcsearch=413%20f%203d%201253&amp;summary=yes#jcite">413 F.3d 1253</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12H5FO003?jcsearch=413%20f%203d%201253&amp;summary=yes#jcite">1273</a> (10th
Cir. 2005)) (internal quotation marks omitted). Regarding the
second prong, we have recognized that error is plain if it is
"clear or obvious under current law." <i>United States v.</i>
<i>Cooper</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1G2F7Q003?jcsearch=654%20f%203d%201104&amp;summary=yes#jcite">654 F.3d 1104</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1G2F7Q003?jcsearch=654%20f%203d%201104&amp;summary=yes#jcite">1117</a> (10th Cir. 2011) (quoting
<i>United States v. Goode</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16LEH4003?jcsearch=483%20f%203d%20676&amp;summary=yes#jcite">483 F.3d 676</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X16LEH4003?jcsearch=483%20f%203d%20676&amp;summary=yes#jcite">681</a> (10th
Cir. 2007)) (internal quotation marks omitted). As for the third
prong of the test, "[i]n the ordinary case," to have the
requisite affect on substantial rights, an error must be
"prejudicial," which means that "there must be a reasonable
probability that the error affected the out-come of the trial."
<i>United States v. Marcus</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1D9VKQ003?jcsearch=130%20S.Ct.%202159&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1D9VKQ003?jcsearch=130%20supreme%20court%202159&amp;summary=yes#jcite">130 S.Ct. 2159</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1D9VKQ003?jcsearch=130%20supreme%20court%202159&amp;summary=yes#jcite">2164</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1D9VKQ003?jcsearch=176%20l%20ed%202d%201012&amp;summary=yes#jcite">176 L.Ed.2d 1012</a> (2010) (internal quotation marks
omitted); <i>accord United States v. Thornburgh</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEI003?jcsearch=645%20f%203d%201197&amp;summary=yes#jcite">645 F.3d 1197</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEI003?jcsearch=645%20f%203d%201197&amp;summary=yes#jcite">1212</a> (10th Cir. 2011); <i>United States v. Fishman</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEK003?jcsearch=645%20f%203d%201175&amp;summary=yes#jcite">645 F.3d 1175</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEK003?jcsearch=645%20f%203d%201175&amp;summary=yes#jcite">1196</a> (10th Cir. 2011). Lastly, as to the fourth
prong, it is notable that there is a relationship between that
prong and the third: "[I]n most circumstances, an error that
does not affect the jury's verdict [i.e., the third prong] does
not significantly impugn the `fairness,' `integrity,' or
`public reputation' of the judicial process [i.e., the fourth
prong]." <i>Marcus</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1D9VKQ003?jcsearch=130%20supreme%20court%202159&amp;summary=yes#jcite">130 S.Ct. at 2166</a> (quoting
<i>Johnson v. United States</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCTH?jcsearch=520%20us%20461&amp;summary=yes#jcite">520 U.S. 461</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCTH?jcsearch=520%20us%20461&amp;summary=yes#jcite">467</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCTH?jcsearch=117%20supreme%20court%201544&amp;summary=yes#jcite">117 S.Ct. 1544</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCTH?jcsearch=137%20l%20ed%202d%20718&amp;summary=yes#jcite">137 L.Ed.2d 718</a> (1997)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We are constrained to conclude that, in propounding Instruction
No. 20 to the jury, the district court committed clear or
obvious error; that there is a reasonable probability that the
error affected the outcome of the trial; and that, under the
circumstances presented here, this error significantly impugned
the fairness, integrity, and public reputation of the trial. In
denying Mr. Bader's post-trial motion for a judgment of
acquittal, the district court concluded that the final sentence
of Instruction No. 20 was "unnecessary," but that any potential
error was harmless.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> Aplee. App., Vol. IV, at 1260-61. We
conclude, however, that the final paragraph of the instruction
was more than "unnecessary"; it effectively allowed the jury to
convict Mr. Bader under a theory upon which he was never
charged &mdash; <i>viz.</i>, illegal importation of <span CLASS="page_no" data-cite="2012 bl 111342 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> an
<i>API</i>, as opposed to illegal importation of <i>a</i>
<i>finished drug product. See id.</i> at 1024-50.
<span CLASS="page_no" data-cite="678 f 3d 869" data-cite-type="PrimaryFederalReporter" data-cite-pageno="869" data-primary-citation="678 F.3d 858">[*869]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under Instruction No. 20, the jury was allowed to convict Mr.
Bader of illegally importing HGH if <i>either</i>: (1) the
imported HGH was a <i>finished drug</i> that did not receive
"new drug approval" from the FDA; <i>or</i> (2) the imported
product was an <i>API</i> that was "manufactured by a foreign
entity that was not registered with the FDA." Aplt. Trial
Tr.App., Vol. VIII, at 2170. This effectively rendered the
"finished drug" versus "API" distinction &mdash; upon which the
government's entire case was based &mdash; a nullity, allowing
the jury to convict Mr. Bader regardless of the imported HGH's
form. In particular, the instruction permitted the jury to
convict Mr. Bader of a charge for which he was never
indicted.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Therefore, in propounding Instruction No. 20 to
the jury, the district court committed clear or obvious error.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We also are convinced that there is a reasonable probability
that this error affected the outcome &mdash; i.e., that there
is a reasonable probability that the jury would not have
convicted Mr. Bader of the <cite>&sect; 545-related</cite> counts but for
this error. <i>See United States v. Marcus</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1EM60S003?jcsearch=628%20f%203d%2036&amp;summary=yes#jcite">628 F.3d 36</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1EM60S003?jcsearch=628%20f%203d%2036&amp;summary=yes#jcite">42</a> (2d Cir. 2010) ("[T]he overall effect of the due process
[instruction-related] error must have been sufficiently great
such that there is a reasonable probability that the jury would
not have convicted him absent the error."). The probable
prejudicial impact of Instruction No. 20 is evident when we
examine it within the context of the entire trial. <i>See</i>
<i>Visinaiz</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X13JGGS003?jcsearch=428%20f%203d%201300&amp;summary=yes#jcite">428 F.3d at 1308</a>. In his closing argument, the
prosecutor invited the jury to consider several email exchanges
between Mr. Bader, Mr. Henry, and Genescience representatives
that "reflect[ed] a concern about whether [the Genescience
facilities] [were] even registered facilities." Aplt.App., Vol.
IX, Tr. at 2760. In one of those email chains, Mr. Henry asked
a Genescience representative whether Genescience was "FDA
registered yet," to which the representative responded that
Genescience "ha[d]n't got registered in FDA yet." <i></i><cite>Id.
at 2767</cite> (Gov't Ex. 34). In another, Mr. Henry informed Mr.
Bader that a representative from Medisca &mdash; apparently an
API supply company &mdash; would be "sending a letter with
information on the FDA[-]registered facility that their HGH
comes from," explaining that the representative was "totally
convinced that Medisca is the only place in the country that is
bringing in [HGH] legally." <i></i><cite>Id. at 2771</cite> (Gov't Ex.
44). In conclusion, Mr. Henry noted, College Pharmacy "need[ed]
to . . . find out if anybody [was] telling the truth or if
they[were] all doing it `illegally.'" <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Jason Woo, Associate Director for Medical and Scientific
Affairs with the Center for Drug Evaluation Research, testified
at trial. When questioned about the FDA approval of
foreign-produced HGH, Dr. Woo explained that "[t]here are no
approved Chinese facilities" &mdash; more specifically, there
are not "any facilities in China that are approved to make any
<i>components</i> of the approved human growth hormone
products." Aplee. App., Vol. I, Tr. at 18 (emphasis added). As
Dr. Woo explained, those "components" &mdash; also known as API
&mdash; are "basically the precursor to an approved drug. [They
are] part of the mix that goes into making <span CLASS="page_no" data-cite="2012 bl 111342 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> the drug."
<i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A reasonable jury presented with this evidence &mdash; the
emails exchanged by Mr. Bader, Mr. Henry, and the Genescience
<span CLASS="page_no" data-cite="678 f 3d 870" data-cite-type="PrimaryFederalReporter" data-cite-pageno="870" data-primary-citation="678 F.3d 858">[*870]</span> 
representative; and the testimony of Dr. Woo &mdash; could
have easily concluded that, even if the imported HGH was not a
"finished drug" subject to NDA oversight, it was still an API
that had been imported contrary to federal law by virtue of its
having been manufactured at a foreign facility that lacked FDA
approval.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> In particular, there is a reasonable probability
that such a jury &mdash; considering this evidence, in
conjunction with the district court's erroneous jury
instruction &mdash; convicted Mr. Bader when it would not
otherwise have done so, on a theory upon which he was never
indicted. Consequently, we conclude that the third prong of the
plain-error test is satisfied. And we discern nothing in the
circumstances of this case that would indicate that such a
prejudicial effect would not significantly impugn the fairness,
integrity, and public reputation of Mr. Bader's trial. Thus, we
conclude that the fourth prong of the plain-error test also is
satisfied. <i>See Marcus</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1EM60S003?jcsearch=628%20f%203d%2036&amp;summary=yes#jcite">628 F.3d at 44</a> (concluding that
there was "a reasonable probability that the erroneous jury
charge affected the outcome of the trial and affected the
fairness, integrity or public reputation of the proceedings").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This plain-error analysis indicates that because of Jury
Instruction No. 20's inclusion of an erroneous theory of
liability &mdash; <i>viz.</i>, a theory that permitted Mr.
Bader's conviction for having imported an API, as opposed to a
finished drug, so long as that API was "manufactured by a
foreign entity that was not registered with the FDA," Aplt.
Trial Tr.App., Vol. VIII, at 2170 (Jury Instruction No. 20)
&mdash; we must reverse and remand. Specifically, we reverse
Mr. Bader's conviction on Count Seventeen, for knowingly
facilitating the sale of HGH imported into the United States
contrary to law, and on Count One, for conspiracy to do so.
Both counts rely on the erroneous liability theory set forth in
Jury Instruction 20.<a HREF="#fn600" name="fnref_fn600">[fn6]</a>
<span CLASS="page_no" data-cite="678 f 3d 871" data-cite-type="PrimaryFederalReporter" data-cite-pageno="871" data-primary-citation="678 F.3d 858">[*871]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>2. Relevancy of Compounding Law</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, Mr. Bader challenges Jury Instruction number twelve
("Jury Instruction No. 12"), pursuant to which the court
informed the jury that "evidence concerning whether Mr. Bader's
actions constituted compounding under various legal
authorities[was] not relevant to the issues" that the jury was
to "resolve under [the court's instructions]." <i></i><cite>Id.
at 2164</cite> (Jury Instruction No. 12). Though Mr. Bader represents
that he "objected" at trial to the court's instruction, he did
not do so on the grounds that he asserts here. <i>See</i>
Aplt.
<span CLASS="page_no" data-cite="678 f 3d 872" data-cite-type="PrimaryFederalReporter" data-cite-pageno="872" data-primary-citation="678 F.3d 858">[*872]</span> 
App., Vol. VIII, Tr. at 2699.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> We therefore review his
claim for plain error. <i>See Willis</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=476%20f%203d%201121&amp;summary=yes#jcite">476 F.3d at 1127</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader argues that the court erroneously "told the jury that
none of these meticulous and required pharmacy processing
standards mattered when, in truth, they controlled the core
questions: whether the [HGH] was already finished prior to
College's purchase, and whether [Mr.] Bader knew this." Aplt.
Opening Br. at 49; <i>see also</i> Aplt. Reply Br. at 12
(noting that "[Mr.] Bader's defense that compounding absolutely
had to occur before this [HGH] was in finished form safe and
ready for patient <span CLASS="page_no" data-cite="2012 bl 111342 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> dispensing was wholly negated by the court's
instruction that all evidence about compounding was
<i>irrelevant</i> "). His objection to Instruction No. 12,
therefore, relates exclusively to his <cite>&sect; 545-related</cite>
charges. As discussed above, however, we must reverse and
vacate Mr. Bader's <cite>&sect; 545-related</cite> convictions on account of
the erroneous "alternative prong" in Instruction No. 20.
Consequently, we need not (and do not) consider whether the
district court's characterization of compounding law as
"irrelevant" obliges us to reverse Mr. Bader's
<cite>&sect; 545-related</cite> convictions; we have already determined that those
convictions cannot stand.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>3. Rejection of State Pharmacy and First Amendment</b>
<b>Instructions</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Mr. Bader argues that the district court erred with
respect to the jury instructions that it did <i>not</i> give
&mdash; i.e., in refusing to inform the jury of Colorado's
pharmacy-dispensing laws, <i>see</i> Aplt. Opening Br.
at 52-54, and in failing to instruct the jury that Mr. Bader "had
a Supreme Court-recognized right to advertise" under the First
Amendment, <i></i><cite>id. at 55</cite>. We review the district court's
refusal to issue these instructions for an abuse of discretion.
<i>See United States v. Crockett</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X142Q6O003?jcsearch=435%20f%203d%201305&amp;summary=yes#jcite">435 F.3d 1305</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X142Q6O003?jcsearch=435%20f%203d%201305&amp;summary=yes#jcite">1314</a>
(10th Cir. 2006). However, in determining "whether the district
court exercised its discretion properly, we review the jury
instructions de novo to determine whether, as a whole, they
accurately state the governing law and provide the jury with an
accurate understanding of the relevant legal standards and
factual issues in the case." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X142Q6O003?jcsearch=435%20F.3d%201305&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Applying this standard to the present case, it is patent that
the district court appropriately exercised its discretion when
it rejected Mr. Bader's proposed instructions. Mr. Bader first
contends that the district court erred in refusing to issue
several "relevant" state pharmacy instructions regarding: (1)
"Colorado requirements that pharmacies maintain adequate drug
inventories and provide adequate services," Aplt. Opening Br.
at 52; (2) "[s]tate laws governing ordering, dispensing[,] and
requirements for valid prescriptions," <i></i><cite>id. at 53</cite>; (3)
"[s]tate laws clarifying that pharmacists who prepare,
compound, package, repackage, or dispense drug[s] are not drug
wholesalers or manufacturers," <i><cite>id</cite>.</i>; and (4) a
"Colorado law providing that pharmacists may rely on a
physician's professional judgment in ordering a drug for a
patient," <i></i><cite>id. at 54</cite>. However, Mr. Bader fails to
identify to which of the forty-three charged counts these state
laws pertain, let alone explain how they are "relevant" to the
charges upon which he was convicted. Indeed, it is clear from
the record that the district court was more than generous in
including "some language [from
<span CLASS="page_no" data-cite="678 f 3d 873" data-cite-type="PrimaryFederalReporter" data-cite-pageno="873" data-primary-citation="678 F.3d 858">[*873]</span> 
the proffered instructions] . . . where it [was] relevant
to [the] explanation of a particular element of a particular
count," despite its determination that Colorado's pharmacy laws
generally had no bearing upon Mr. Bader's charges. <i>See</i>
Aplee. App., Vol. III, Tr. at 634. As Mr. Bader offers no
support for his bald allegation that this determination was
somehow erroneous, we are constrained to conclude that his
first argument is meritless.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's undeveloped First Amendment claim, which he seeks
to assert <span CLASS="page_no" data-cite="2012 bl 111342 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> throughout his opening brief, is even less
persuasive. As we discuss <i>infra</i>, the government
introduced evidence of College Pharmacy advertisements in order
to prove that Mr. Bader purposefully marketed HGH and
testosterone cypionate for impermissible purposes. At no point,
however, did the government contest, as a general matter,
College Pharmacy's right to advertise its products. In other
words, Mr. Bader's First Amendment right to advertise was in no
way implicated, let alone compromised, by the charges against
him. Consequently, an instruction regarding Mr. Bader's First
Amendment rights could not possibly have promoted an "accurate
understanding of the relevant legal standards and factual
issues in the case." <i>See Crockett</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X142Q6O003?jcsearch=435%20f%203d%201305&amp;summary=yes#jcite">435 F.3d at 1314</a>.
We therefore reject Mr. Bader's unsubstantiated assertion that
the district court somehow abused its discretion in refusing to
issue an (irrelevant) instruction pertaining to his First
Amendment right to advertise.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>B. <i>Sufficiency of the Evidence</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader avers that there was insufficient evidence to support
his convictions, renewing many of the unsuccessful arguments
that he asserted in his Renewed Motion for Judgment of
Acquittal and Alternative Motion for a New Trial that he filed
post-trial. We review de novo the sufficiency of the evidence
upon which Mr. Bader was convicted, "ask[ing] only whether
taking the evidence &mdash; both direct and circumstantial,
together with the reasonable inferences to be drawn therefrom
&mdash; in the light most favorable to the government, a
reasonable jury could find the defendant guilty beyond a
reasonable doubt." <i>United States v. McCane</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1BD3G0003?jcsearch=573%20f%203d%201037&amp;summary=yes#jcite">573 F.3d 1037</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1BD3G0003?jcsearch=573%20f%203d%201037&amp;summary=yes#jcite">1046</a> (10th Cir. 2009) (alteration in original) (quoting
<i>United States v. Brown</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XVOBT3?jcsearch=400%20f%203d%201242&amp;summary=yes#jcite">400 F.3d 1242</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XVOBT3?jcsearch=400%20f%203d%201242&amp;summary=yes#jcite">1247</a> (10th
Cir. 2005)) (internal quotation marks omitted). "Rather than
examining the evidence in `bits and pieces,' we evaluate the
sufficiency of the evidence by `consider[ing] the collective
inferences to be drawn from the evidence as a whole.'"
<i>United States v. Wilson</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3AP3P?jcsearch=107%20f%203d%20774&amp;summary=yes#jcite">107 F.3d 774</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3AP3P?jcsearch=107%20f%203d%20774&amp;summary=yes#jcite">778</a> (10th
Cir. 1997) (alteration in original) (quoting <i>United States</i>
<i>v. Hooks</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XABRFS?jcsearch=780%20f%202d%201526&amp;summary=yes#jcite">780 F.2d 1526</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XABRFS?jcsearch=780%20f%202d%201526&amp;summary=yes#jcite">1532</a> (10th Cir. 1986)),
<i>abrogated on other grounds</i> as <i>recognized by United</i>
<i>States v. King</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ES4IM003?jcsearch=632%20f%203d%20646&amp;summary=yes#jcite">632 F.3d 646</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ES4IM003?jcsearch=632%20f%203d%20646&amp;summary=yes#jcite">651-52</a> &amp; n. 5 (10th
Cir. 2011); <i>accord United States v. McGehee</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1H5SKO003?jcsearch=672%20f%203d%20860&amp;summary=yes#jcite">672 F.3d 860</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1H5SKO003?jcsearch=672%20f%203d%20860&amp;summary=yes#jcite">871</a> (10th Cir. 2012). In so doing, "we may not assess the
credibility of witnesses or weigh conflicting evidence, as
these tasks are exclusively for the jury." <i>United States v.</i>
<i>Bowen</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VS40003?jcsearch=527%20f%203d%201065&amp;summary=yes#jcite">527 F.3d 1065</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VS40003?jcsearch=527%20f%203d%201065&amp;summary=yes#jcite">1076</a> (10th Cir. 2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>1. Unlawful Distribution or Possession with Intent to</b>
<b>Distribute HGH</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In order to convict Mr. Bader of unlawful possession with
intent to distribute HGH in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e), the government was obligated to prove each of three
elements beyond a reasonable doubt: (1) that Mr. Bader
knowingly distributed HGH or possessed HGH with the intent to
distribute it; (2) that Mr. Bader knew that the HGH that he
possessed and intended to distribute was for use in humans; and
(3) "[e]ither [that] Mr. Bader knew that
<span CLASS="page_no" data-cite="678 f 3d 874" data-cite-type="PrimaryFederalReporter" data-cite-pageno="874" data-primary-citation="678 F.3d 858">[*874]</span> 
the [HGH] was not being distributed for a[] use authorized
by the Secretary of Health and Human Services[,] or that Mr.
Bader knew that the [HGH] was not being distributed pursuant to
the order of a physician[,] or was not being prescribed for a
valid medical purpose." <span CLASS="page_no" data-cite="2012 bl 111342 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> Aplt. Trial Tr. App., Vol. VIII,
at 2180-81 (Jury Instruction No. 38). Mr. Bader challenges the
third of these three elements on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader principally argues that his conviction cannot stand
because the government failed to present proof that he
knowingly filled a prescription for an unauthorized use &mdash;
"[i]llegal distribution," he contends, "requires proof of a
prescription sale for an unapproved use <i>and</i> that a
pharmacist knowingly filled it." Aplt. Opening Br. at 31. This
is simply incorrect. Under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e)(1),
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  whoever knowingly distributes, or possesses with
  intent to distribute, human growth hormone for any use
  in humans <i>other than</i> the treatment of a
  disease or other recognized medical condition, where
  such use has been authorized by the Secretary of
  Health and Human Services under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355&amp;summary=yes#jcite">section 355</a> of this
  title and pursuant to the order of a physician, is
  guilty of an offense punishable by not more than 5
  years in prison, such fines as are authorized by
  Title 18, or both.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20usc%20333&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e)(1) (emphasis added). Thus, the plain
terms of the statute belie Mr. Bader's argument &mdash;
specifically, his contention that there is only one means to
violate the statute involving knowingly filling a prescription
for an unauthorized use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, Jury Instruction No. 38 &mdash; the instruction that
outlined the elements of the unlawful distribution charge
<i>and</i> to which Mr. Bader has offered no objection
&mdash; was phrased in the disjunctive. According to that
instruction, proof of the filling of an improper physician
prescription was but one of three ways that the government
could satisfy its burden. The government could demonstrate
<i>either</i>: (1) that "Mr. Bader knew that the [HGH] was
not being distributed for a[] use authorized by the Secretary
of Health and Human Services"; "<i>or</i> [(2)] that Mr.
Bader knew that the [HGH] was not being distributed pursuant to
the order of a physician"; "<i>or</i> [(3) that Mr. Bader
knew that the HGH that he possessed] was not being prescribed
for a valid medical purpose." Aplt. Trial Tr. App., Vol. VIII,
at 2181 (emphases added).<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Throughout Mr. Bader's trial, the government introduced a
series of exhibits consisting of College Pharmacy
advertisements that extolled the anti-aging and muscle-building
benefits of HGH, as well as related statements from Mr. Blum
and various College Pharmacy employees. Several of the
witnesses who testified recalled that Mr. Bader had promoted
HGH at A4M trade shows as an anti-aging and body-building drug.
And their testimony was corroborated by photographs depicting
Mr. Bader and his advertisements at one of these trade shows.
Mr. Bader apparently argues that this evidence is insufficient
because it merely demonstrates promotion, as opposed to actual
distribution, of HGH. However, under the plain language of the
statute &mdash; as well as Mr. Bader's counts of conviction
&mdash; proscribed is not only the actual distribution of HGH
but also <i>possession with intent to distribute.</i>
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e). As it is undisputed
<span CLASS="page_no" data-cite="678 f 3d 875" data-cite-type="PrimaryFederalReporter" data-cite-pageno="875" data-primary-citation="678 F.3d 858">[*875]</span> 
that College Pharmacy "possessed" HGH at its Colorado
Springs facility, any rational trier of fact could have
concluded that these advertisements demonstrated Mr. Bader's
intent to market and <span CLASS="page_no" data-cite="2012 bl 111342 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> distribute HGH as an anti-aging and
body-building drug, which were not authorized uses of HGH.<a HREF="#fn900" name="fnref_fn900">[fn9]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In that regard, the government introduced evidence
demonstrating that the FDA had not approved the use of HGH for
either anti-aging or body-building purposes through the
testimony of Dr. Woo. After establishing that his position as
medical director had familiarized him with the process that a
pharmaceutical manufacturer must undergo in order to obtain FDA
approval for a drug such as HGH, Dr. Woo informed the jury that
HGH had yet to be approved for <i>any</i> off-label uses due
to congressional safety concerns.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> Specifically, Dr. Woo
also testified that bodybuilding and anti-aging were
<i>not</i> FDA-approved "uses" for HGH. On the basis of this
evidence, a reasonable jury could have logically deduced that
the College Pharmacy anti-aging and body-building
advertisements introduced at trial were aimed at distributing
HGH for those uses &mdash; uses which had yet to be authorized
by the Secretary of Health and Human Services or recognized as
valid medical conditions warranting HGH prescriptions.
Accordingly, a reasonable jury could have construed this
evidence as satisfying the third element of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>2. Facilitating the Sale of Illegally Imported HGH and</b>
<b>Conspiracy to Facilitate the Sale of Illegally Imported</b>
<b>HGH</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While we must vacate Mr. Bader's <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>-related
convictions of facilitating the sale of illegally imported HGH
and conspiracy to facilitate that sale due to the
aforementioned error in Jury Instruction No. 20, standing
alone, this action would not preclude the government from
re-prosecuting Mr. Bader on these charges. It is the law of
this circuit that the reversal of a defendant's conviction
"bars retrial only where the government presents no evidence
that could support [his] conviction." <i>United States v.</i>
<i>Holly</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17677S003?jcsearch=488%20f%203d%201298&amp;summary=yes#jcite">488 F.3d 1298</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17677S003?jcsearch=488%20f%203d%201298&amp;summary=yes#jcite">1311</a> n. 11 (10th Cir. 2007);
<i>accord United States v. Pearl</i>,
<span CLASS="page_no" data-cite="678 f 3d 876" data-cite-type="PrimaryFederalReporter" data-cite-pageno="876" data-primary-citation="678 F.3d 858">[*876]</span> 
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CHFF?jcsearch=324%20f%203d%201210&amp;summary=yes#jcite">324 F.3d 1210</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CHFF?jcsearch=324%20f%203d%201210&amp;summary=yes#jcite">1214</a> (10th Cir. 2003) ("Our conclusion that
[defendant's] convictions on counts 2 through 5 must be
reversed does not, however, preclude retrial of [defendant] on
these counts. . . ."); <i>cf. Level 3 Commc'ns v. Liebert</i>
<i>Corp.</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X19AGFK003?jcsearch=535%20f%203d%201146&amp;summary=yes#jcite">535 F.3d 1146</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X19AGFK003?jcsearch=535%20f%203d%201146&amp;summary=yes#jcite">1150</a> (10th Cir. 2008) (vacating the
jury's verdict and remanding for a <i>new trial</i> where the
court erroneously instructed the jury).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This principle is grounded in the Double Jeopardy Clause. In
contrast to a second trial following an acquittal, which would
"present an unacceptably high risk that the [g]overnment, with
its vastly superior resources, might wear down the defendant so
that `even though innocent, he may be found guilty,'"
<i>United States v. Scott</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=437%20us%2082&amp;summary=yes#jcite">437 U.S. 82</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=437%20us%2082&amp;summary=yes#jcite">91</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=98%20supreme%20court%202187&amp;summary=yes#jcite">98 S.Ct. 2187</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=57%20l%20ed%202d%2065&amp;summary=yes#jcite">57 L.Ed.2d 65</a> (1978) (quoting <i>Green v. United</i>
<i>States</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C3MM?jcsearch=355%20us%20184&amp;summary=yes#jcite">355 U.S. 184</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C3MM?jcsearch=355%20us%20184&amp;summary=yes#jcite">188</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C3MM?jcsearch=78%20supreme%20court%20221&amp;summary=yes#jcite">78 S.Ct. 221</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C3MM?jcsearch=2%20l%20ed%202d%20199&amp;summary=yes#jcite">2 L.Ed.2d 199</a>
(1957)), the Supreme Court has held that "the successful appeal
of a judgment of conviction, on any ground other than the
insufficiency of the evidence to support the verdict . . .
poses no bar to further prosecution on the same charge" because
"to require a criminal defendant to stand trial again after he
has successfully invoked a statutory right of appeal to upset
his first conviction is not an act of governmental oppression
of the sort against which the Double Jeopardy Clause was
intended to protect," <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=437%20U.S.%2082&amp;summary=yes#jcite">id at 90-91</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C9KO?jcsearch=98%20supreme%20court%202187&amp;summary=yes#jcite">98 S.Ct. 2187</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, <span CLASS="page_no" data-cite="2012 bl 111342 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> this circuit has established a distinction between
"trial error" deriving from an erroneous jury instruction and
"pure insufficiency of evidence" such that, in the former case,
a defendant "may be retried without violating double jeopardy."
<i>Pearl</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CHFF?jcsearch=324%20f%203d%201210&amp;summary=yes#jcite">324 F.3d at 1214</a>; <i>accord United States v.</i>
<i>Wacker</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X39TLP?jcsearch=72%20f%203d%201453&amp;summary=yes#jcite">72 F.3d 1453</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X39TLP?jcsearch=72%20f%203d%201453&amp;summary=yes#jcite">1465</a> (10th Cir. 1995). Thus, Mr.
Bader may be retried following remand to the district court
<i>if</i> his case falls within this "trial error" category
&mdash; in other words, so long as the government presented
legally sufficient evidence. <i>See United States v.</i>
<i>Nacchio</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18KUSS003?jcsearch=519%20f%203d%201140&amp;summary=yes#jcite">519 F.3d 1140</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18KUSS003?jcsearch=519%20f%203d%201140&amp;summary=yes#jcite">1157</a> (10th Cir. 2008) ("Although we
have concluded that Mr. Nacchio's conviction must be reversed
on account of trial error, we cannot leave it at that. He also
claims that the government failed to introduce evidence
sufficient for him to be convicted. If he is right, he was
entitled to a judgment of acquittal and cannot be retried
without violating the Double Jeopardy Clause."), <i>vacated in</i>
<i>part on other grounds</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1AKJVK003?jcsearch=555%20f%203d%201234&amp;summary=yes#jcite">555 F.3d 1234</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1AKJVK003?jcsearch=555%20f%203d%201234&amp;summary=yes#jcite">1236</a> (10th
Cir. 2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Perhaps because he is aware of this fact, Mr. Bader devotes a
substantial portion of his briefs to challenging the
sufficiency of the evidence supporting his <cite>&sect; 545-related</cite>
convictions. Specifically, he avers that: (1) his convictions
cannot stand because they were premised upon the importation of
an <i>API</i> rather than a finished drug &mdash; i.e., that
a reasonable jury could not have concluded that the imported
HGH was a "finished drug" on the basis of the evidence that the
government produced at trial; (2) the record contains no
evidence that Mr. Bader possessed the requisite <i>mens</i>
<i>rea</i> to be convicted of the importation of HGH contrary to
law; and (3) the government failed to prove that Mr. Bader
knowingly participated with a specific intent to further the
conspiracy to sell contraband HGH. Aplt. Opening Br.
at 21-30.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> None of these arguments has merit.
<span CLASS="page_no" data-cite="678 f 3d 877" data-cite-type="PrimaryFederalReporter" data-cite-pageno="877" data-primary-citation="678 F.3d 858">[*877]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
            <b>(i) Importation of Illegally Manufactured API or</b>
               <b>Finished Drug Product Lacking NDA Approval</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader insists that a reasonable jury could not have
convicted him of the <cite>&sect; 545-related</cite> charges because the
government failed to sufficiently demonstrate that the imported
HGH was a "finished" drug product rather than an API. Though as
noted we find error with the dual avenues that Jury Instruction
No. 20 provided for conviction, there was ample evidence upon
which a reasonable jury could have convicted Mr. Bader on the
proper ground specified in this instruction: that is, the
imported HGH was a finished drug that was illegally imported on
account of Mr. Bader's failure to garner NDA approval.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
<span CLASS="page_no" data-cite="678 f 3d 878" data-cite-type="PrimaryFederalReporter" data-cite-pageno="878" data-primary-citation="678 F.3d 858">[*878]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Specifically, the government produced sufficient evidence upon
which a reasonable jury could have concluded that the HGH that
Mr. Bader imported was a "finished drug" &mdash; primarily
through detailed witness testimony explaining how the imported
Genescience HGH remained essentially unaltered prior to
distribution. Much of this testimony pertained to the specific,
step-by-step protocol that College Pharmacy employees followed
in preparing the imported Chinese HGH for distribution. Stacy
Griffin, one of those employees, read portions of College
Pharmacy's "Somatropin prepackaged protocol" aloud from <span CLASS="page_no" data-cite="2012 bl 111342 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> the
stand as she testified. Aplee. App., Vol. I, Tr. at 131 (Test,
of Stacy Griffin). That protocol was remarkably simple,
requiring College Pharmacy employees to simply gather and
sterilize "5 cc 20-millimeter vials," clean the requisite
measuring materials, calibrate the scales used to weigh out the
appropriate doses, then "[p]lace [an] empty sterile vial on the
balance and begin to weigh powder into it." <i></i><cite>Id.
at 132-34</cite> (internal quotation marks omitted). Ms. Griffin verified
that this was "essentially the process that was followed when
College Pharmacy took the Somatropin from the large bottles and
put it into small vials," <i></i><cite>id. at 134</cite>, and confirmed
that College Pharmacy "got Somatropin from" Genescience,
<i></i><cite>id. at 131</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  John Ruth, a College Pharmacy national sales representative,
also told the jury that, at least initially, College Pharmacy
did no more than simply "repackag[e]" the imported HGH.
<i><cite>Id</cite>.</i>, Vol. II, Tr. at 296 (Test, of John Ruth). Mr.
Ruth explained that College Pharmacy employees were "told via
Mr. Bader" to repackage the imported HGH, and that the College
Pharmacy sales team, in turn, "told all of [its] clients and
prospective clients" the same thing: College Pharmacy was
"bringing in a drug, importing it from another country, and
. . . repackaging [it] into [College Pharmacy's] own package and
selling it to them." <i><cite>Id</cite>.</i> Then, "in early 2005, after
[College Pharmacy] had been selling the Somatropin for several
months and had done well, [the sales team was] told . . . that
[it was] not repackaging [the HGH] because [it] could not get a
license to repackage from the . . . FDA." <i><cite>Id</cite>.</i> The
College Pharmacy sales team then simply began to inform
customers that the HGH "was compounded; that it was no longer
repackaged." <i><cite>Id</cite>.</i> Any change in College Pharmacy's
Genescience processes &mdash; from "repackaging" to
"compounding" &mdash; was therefore illusory, and was aimed at
avoiding FDA oversight rather than actually "compounding"
imported ingredients.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The testimony of Ms. Griffin and Mr. Ruth was corroborated by
the testimony of Mr. Blum, who stated that he was not aware of
"anything being added or taken out of the bottled version [of
HGH] that [Genescience] provided [College Pharmacy] [as
juxtaposed with] the vials that [College Pharmacy was] putting
out." <i><cite>Id</cite>.</i>, Vol. I, Tr. at 182 (Test, of Brad Blum).
Mr. Blum consistently referred to the Genescience HGH product
that he sold to Mr. Bader as "Somatropin," and even testified
that he "personal[ly] use[d]" Somatropin after purchasing it
directly from Genescience. <i></i><cite>Id. at 168-69</cite>. Upon
receiving the Genescience shipment from China, Mr. Blum
explained, he mixed the imported vial of HGH powder with a vial
of water and injected himself with the hormone at his home,
noting that HGH enables one to "recover faster from injury" and
that he found it to improve his "general well being."
<span CLASS="page_no" data-cite="678 f 3d 879" data-cite-type="PrimaryFederalReporter" data-cite-pageno="879" data-primary-citation="678 F.3d 858">[*879]</span> 
<i></i><cite>Id. at 170</cite>. On the basis of testimony from the man
who actually imported and dealt directly with Genescience, it
would have been entirely reasonable for a jury to conclude that
Genescience's HGH, to which nothing was "being added or taken
out," was essentially (in substance) identical to the smaller
Somatropin doses that College Pharmacy later marketed &mdash;
particularly in light of Mr. Blum's testimony that he was <span CLASS="page_no" data-cite="2012 bl 111342 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> able
to personally use (as well as distribute to his friends) the
"finished" HGH that he received directly from Genescience.
<i>See </i><cite>id. at 172</cite>, 182.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having learned (1) that the imported Genescience HGH was merely
repackaged into smaller vials as "Somatropin," (2) that College
Pharmacy employees themselves told clients they were merely
repackaging the imported HGH, and (3) that the imported
Genescience HGH was &mdash; at least in certain significant
instances (e.g., the use of Mr. Blum) &mdash; patient-ready
even prior to College Pharmacy's processing, a reasonable jury
could have easily inferred that the imported Genescience HGH
was already in its "finished" form when it arrived at College
Pharmacy for repackaging and distribution. In sum, Mr. Bader's
conviction was supported by a wealth of evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              <b>(ii) <i>Mens Rea</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader also argues that the government failed to present
sufficient evidence that he possessed the necessary <i>mens</i>
<i>rea</i> to be convicted under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>.
<i>See</i> Aplt. Opening Br. at 28. Neither party does a good
job of developing this issue. And, in particular, the
government's conclusory assertion that "[i]t was uncontroverted
that [Mr. Bader] knew the [HGH] in question was not the subject
of an approved NDA," Aplee. Br. at 23 &mdash; with no citations
to the record that support this statement &mdash; is unhelpful.
Our independent review of the record, however, confirms that
the government is correct: a reasonable jury could have easily
concluded that Mr. Bader knew the illicit nature of his `
transactions on the basis of the evidence adduced at trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Admittedly, our own circuit has offered little in the way of
guidance regarding the <i>mensrea</i> requirement of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a>. Our sister circuits, however, have observed that "the word
`knowingly'" &mdash; as it appears in <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a> &mdash;
"modifies `imports or brings into the United States, any
merchandise contrary to law.'" <i>United States v.</i>
<i>Garcia-Paz</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XACAS9?jcsearch=282%20f%203d%201212&amp;summary=yes#jcite">282 F.3d 1212</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XACAS9?jcsearch=282%20f%203d%201212&amp;summary=yes#jcite">1217</a> (9th Cir. 2002) (quoting
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>); <i>accord United States v. Molt</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XABBT6?jcsearch=615%20f%202d%20141&amp;summary=yes#jcite">615 F.2d 141</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XABBT6?jcsearch=615%20f%202d%20141&amp;summary=yes#jcite">146</a> (3d Cir. 1980) ("An essential element of a
<cite>section 545</cite> offense is . . . a knowing importation of merchandise
contrary to law."); <i>see also Roseman v. United States</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3RP31?jcsearch=364%20f%202d%2018&amp;summary=yes#jcite">364 F.2d 18</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3RP31?jcsearch=364%20f%202d%2018&amp;summary=yes#jcite">23</a> (9th Cir. 1966) (noting that an appellant's
charge under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a> for the sale of LSD required
proof "(1) that the appellants sold the LSD"; "(2) that [the]
appellants had <i>knowingly brought this LSD into the United</i>
<i>States contrary to law</i>"; "and (3) that the LSD . . . was a
`new drug" . . . for which there was no effective new drug
application" (emphasis added)). Under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a>, "[i]t is not a
requirement of the offense that the defendant know the type of
merchandise he is importing. He need only know that he is
importing or bringing in `merchandise contrary to law.'"
<i>Garcia-Paz</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XACAS9?jcsearch=282%20f%203d%201212&amp;summary=yes#jcite">282 F.3d at 1217</a> (quoting
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>). In the present case, therefore, the government could
satisfy <cite>&sect; 545</cite>'s <i>mensrea</i> requirement so long as it
could demonstrate that Mr. Bader "knew" that he was importing a
drug from Genescience illegally.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As proof that Mr. Bader possessed the requisite <i>mens</i>
<i>rea</i> to be convicted of a <cite>&sect; 545-related</cite> offense, the
government first presented the testimony of
<span CLASS="page_no" data-cite="678 f 3d 880" data-cite-type="PrimaryFederalReporter" data-cite-pageno="880" data-primary-citation="678 F.3d 858">[*880]</span> 
Chris Strong, College Pharmacy's managing pharmacist at the
time that Mr. Bader began importing the Chinese HGH. Mr. Strong
testified that he had expressed his concerns about the
importation of Chinese HGH to Mr. Bader and <span CLASS="page_no" data-cite="2012 bl 111342 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[**16]</span> other College
Pharmacy pharmacists at a meeting in 2004. He explained that
the meeting had centered upon whether or not College Pharmacy
was "going to operate the pharmacy with the compliance policy
guidelines of the FDA," and he recalled that "Mr. Bader's
opinion [had been] that [the FDA's policy] was a guideline"
&mdash; <i>not</i> "a rule or a regulation" that College
Pharmacy was obligated to follow. Aplee. App., Vol. I, Tr.
at 113 (Test, of Chris Strong); <i>see also <cite>id</cite>.</i>, Vol. II,
Tr. at 293-94 ("[T]he FDA wanted in, and [Mr. Bader] wanted
them out. . . . [T]hey were known as Big Pharma. They were the
big enemy, and we were the good guys."). Mr. Strong further
testified that he and Mr. Bader had quarreled over appropriate
College Pharmacy protocol, usually in relation to Mr. Bader's
continuous attempts to increase College Pharmacy's profit. Not
long after Mr. Strong attempted to institute a new policy at
College Pharmacy &mdash; pursuant to which pharmacists would be
asked to verify that any new physician who sought to fill a
prescription with College Pharmacy was adequately certified
&mdash; he was fired from his position at the pharmacy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's knowing disregard of the FDA's regulatory scheme
was directly confirmed by the testimony of Mr. Blum, who
admitted that both he and Mr. Bader had known that the
Genescience HGH was not an FDA-approved product and had also
known that it was being imported from China. Mr. Ruth also told
the jury that Mr. Bader had known that the imported HGH was
subject to FDA approval, and recounted how Mr. Bader had
directed his sales staff to inform College Pharmacy customers
that the pharmacy was "compound[ing]" rather than merely
"repackaging" the imported HGH in order to avoid FDA licensing
requirements. <i><cite>Id</cite>.</i>, Vol. II, Tr. at 296.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A reasonable jury certainly could have construed the testimony
of Mr. Strong, Mr. Blum, and Mr. Ruth &mdash; particularly when
viewed collectively &mdash; as constituting sufficient evidence
that Mr. Bader "knowingly" imported HGH from Genescience and
that he knew that he was doing so "contrary to law."
<i>See</i> <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>; <i>see Garcia-Paz</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XACAS9?jcsearch=282%20f%203d%201212&amp;summary=yes#jcite">282 F.3d at 1217</a>. As such, the government presented sufficient
evidence upon which a reasonable jury could have concluded that
the <i>mens rea</i> element of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a> was satisfied.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>3. Conspiracy</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Mr. Bader contends that the government failed to prove
that he conspired with Mr. Blum and others to illegally import
HGH, alleging that (1) "the [g]overnment failed to prove
anything other than an equipoise buyer-seller relationship
between [Mr.] Blum and the purchasing pharmacies," and (2) that
the government failed to prove that he knowingly participated
in the alleged conspiracy. Aplt. Opening Br. at 29. The
district court here instructed the jury that, in order to
convict Mr. Bader of conspiring to violate <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>,
the government was obligated to prove, beyond a reasonable
doubt, that "(1) Mr. Bader entered into an agreement or
understanding with one or more others to import [HGH] into the
United States contrary to federal law and thereafter to sell or
distribute that [HGH] within the United States"; (2) "[t]here
was an interdependence among Mr. Bader and the others involved
in [the] agreement"; (3) "Mr. Bader knew that the <span CLASS="page_no" data-cite="2012 bl 111342 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[**17]</span> purpose of
the agreement was to import the [HGH] contrary to federal
law[,]" to sell it thereafter, and that he
<span CLASS="page_no" data-cite="678 f 3d 881" data-cite-type="PrimaryFederalReporter" data-cite-pageno="881" data-primary-citation="678 F.3d 858">[*881]</span> 
"voluntarily entered into that agreement"; and (4) "[o]ne
or more of the people who entered into the agreement performed
one or more overt acts &mdash; that is, actions that
constituted a substantial step towards achieving the purpose"
of the illegal importation scheme.<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> Aplt. Trial Tr. App.,
Vol. VIII, at 2168 (Jury Instruction No. 18); <i>see also</i>
<i>Molt</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XABBT6?jcsearch=615%20f%202d%20141&amp;summary=yes#jcite">615 F.2d at 146</a> (discussing elements of crime of
conspiring to violate <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">&sect; 545</a>). Mr. Bader arguments implicate
only the first and third elements. The government, however,
presented ample evidence to support the jury's findings as to
these elements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, on redirect, Mr. Blum clearly and unequivocally
testified that he illegally imported and distributed HGH, and
that he did so with Mr. Bader's knowledge and assistance. Mr.
Blum acknowledged that he had "agree[d] to violate the law"
when he "agreed to do business with Tom Bader," and he further
admitted that this agreement amounted to a conspiracy involving
"importation of [HGH] and delivery to Mr. Bader," that the
"essential objective of the conspiracy" was to "distribute
[HGH]," and that the "members of that conspiracy" were
"[him]self and Tom [Bader]." Aplee. App., Vol. I, Tr. at 252.
Mr. Blum also confirmed that Mr. Bader had "knowingly and
voluntarily participated in that agreement." <i><cite>Id</cite>.; see</i>
<i></i><cite>id. at 189</cite> (agreeing that "Mr. Bader . . . kn[e]w that
this was not FDA[-]approved product").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Blum's statements were corroborated by the testimony of Mr.
Strong, who told the jury that Mr. Bader was aware of the fact
that his importation of Genescience HGH violated FDA protocol,
as well as the testimony of Mr. Ruth, who confirmed that
College Pharmacy was purchasing HGH from Mr. Blum and from
Genescience in China at the direction of Mr. Bader. On the
basis of this testimony, a reasonable jury could have concluded
that Mr. Bader "knowingly" entered into an agreement with Mr.
Blum to import and distribute HGH in a manner that Mr.
<span CLASS="page_no" data-cite="678 f 3d 882" data-cite-type="PrimaryFederalReporter" data-cite-pageno="882" data-primary-citation="678 F.3d 858">[*882]</span> 
Bader knew was "contrary to law" &mdash; i.e., in a way
that he knew ran afoul of FDA rules and regulations.
Accordingly, we conclude that the government presented
sufficient evidence of Mr. Bader's involvement in a conspiracy
relating to the <cite>&sect; 545</cite> charge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>4. Conspiracy to Distribute or Possess with Intent to</b>
<b>Distribute Testosterone Cypionate</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Mr. Bader challenges the sufficiency of the evidence
that the government presented to prove Count Nineteen of the
Superseding Indictment &mdash; conspiracy to distribute and to
possess with the intent to distribute testosterone cypionate
(an anabolic steroid), in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976D8003?jcsearch=21%20U.S.C.%20%20841(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 841</a>(a)(1), <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976D8003?jcsearch=21%20U.S.C.%20%20841(b)(1)(D)&amp;summary=yes#jcite">(b)(1)(D)</a>, and <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976DK003?jcsearch=21%20usc%20846&amp;summary=yes#jcite">21 U.S.C. &sect; 846</a>. Mr. Bader argues
that, of the nearly four thousand doctors that College Pharmacy
serviced, only two admitted that they had "secretly" prescribed
testosterone through College Pharmacy for unlawful uses. Aplt.
Opening Br. at 56. He also avers that he was unaware of these
unlawful prescriptions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the jury was instructed at trial, the government bore the
burden of proving, beyond a reasonable doubt, that: "(1) Mr.
Bader entered into an agreement or understanding with one or
more others to unlawfully distribute or to possess . . . <span CLASS="page_no" data-cite="2012 bl 111342 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[**18]</span> with
the intention of unlawfully distributing a controlled
substance; namely, testosterone cypionate, an anabolic
steroid"; "(2) Mr. Bader knew that the purpose of the
agreement" was to unlawfully distribute or to possess with
intent to distribute that testosterone cypionate; and "(3)
[t]here was an interdependence among Mr. Bader and the others
involved in this agreement or understanding." Aplt. Trial
Tr.App., Vol. VIII, at 2178 (Jury Instruction No. 84). Mr.
Bader contests the government's proof of the first two of these
three elements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                 <b>(i) Agreement to Unlawfully Distribute</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Mr. Bader primarily attempts to discredit the
government's evidence regarding the two doctors who prescribed
testosterone cypionate for unlawful uses through prescriptions
filled by College Pharmacy,<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a> this was merely one aspect of
the abundant evidence that the government presented to
demonstrate that Mr. Bader knowingly agreed with other College
Pharmacy sales and advertising staff to illegally distribute
and to possess with the intent to distribute testosterone
cypionate. First, to prove that an agreement existed, the
government presented testimony from one of Mr. Bader's
co-conspirators. Specifically, Mr. Ruth testified that he
"always got instruction from
<span CLASS="page_no" data-cite="678 f 3d 883" data-cite-type="PrimaryFederalReporter" data-cite-pageno="883" data-primary-citation="678 F.3d 858">[*883]</span> 
Thomas Bader" regarding how he and fellow College Pharmacy
employee, Kevin Henry, should prepare for and present
information at the A4M anti-aging conferences at which College
Pharmacy marketed testosterone cypionate, Aplee. App., Vol. II,
Tr. at 298 &mdash; despite the fact that anti-aging is not a
lawful, approved use for this drug. Sometimes Mr. Bader even
attended these conferences himself and, when he did, Mr. Bader
was the one "running the show." <i><cite>Id</cite>.</i>, Vol. I, Tr.
at 191. Mr. Ruth also explained that College Pharmacy had enjoyed
a lucrative relationship with Peak Physique, a large anti-aging
clinic that purchased large volumes of prescriptions from
College Pharmacy, and that Mr. Bader had supervised the Peak
Physique account.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, the government introduced a series of College
Pharmacy's advertisements promoting testosterone for anti-aging
and body-building purposes.<a HREF="#fn1500" name="fnref_fn1500">[fn15]</a> Among these was a printout of
College Pharmacy's web page, which depicted a bulging bicep and
the word "TESTOSTERONE" in large, block print, accompanied, at
the top of the page, by these words: "Recent headlines question
the benefits of testosterone for aging men . . . To learn more,
click here."<a HREF="#fn1600" name="fnref_fn1600">[fn16]</a> <i><cite>Id</cite>.</i>, Vol. Ill, at 657 (Gov't Ex.
23) (some capitalization altered). Mr. Ruth testified that this
advertisement was geared toward promoting "[b]ig muscles," and
that Mr. Bader himself had approved it. <i><cite>Id</cite>.</i>, Vol. II,
Tr. at 318. Government Exhibit Thirteen &mdash; a College
Pharmacy print advertisement encouraging consumers to "[l]ive
[l]ife to the [f]ullest" &mdash; also billed "[t]estosterone
for [m]en &amp; [w]omen" as one of College Pharmacy's featured
anti-aging products, and boasted that "[a]nti-[a]ging clinics
all over the United States [were] coming to College Pharmacy
for solutions to their age[-]management questions."
<i><cite>Id</cite>.</i>, Vol. Ill, at 645 (Gov't Ex. 13). Mr.
Ruth explained that Tracy Crawford, College Pharmacy'<span CLASS="page_no" data-cite="2012 bl 111342 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[**19]</span> s managing
director of sales, had affixed a post-it note to this
advertisement asking Mr. Bader whether he would like to include
it as an insert in the registration bags that College Pharmacy
distributed to anti-aging trade show attendees.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, Mr. Ruth confirmed that <i>all</i> of College
Pharmacy marketing materials and major decisions were subject
to Mr. Bader's approval. His testimony, combined with these
College Pharmacy advertisements, provided more than sufficient
evidence upon which a reasonable jury could have concluded that
Mr. Bader "entered into an agreement" with Mr. Ruth and other
members of the sales department to unlawfully distribute
testosterone cypionate &mdash; in other words, the government
<span CLASS="page_no" data-cite="678 f 3d 884" data-cite-type="PrimaryFederalReporter" data-cite-pageno="884" data-primary-citation="678 F.3d 858">[*884]</span> 
met its burden of proof concerning element one of Count
Nineteen under Jury Instruction No. 34. <i>See</i> Aplt.
Trial Tr. App., Vol. VIII, at 2178; <i>see </i><cite>id. at 2168-69</cite>
(Jury Instruction No. 19) ("In determining whether the
[g]overnment has shown that Mr. Bader entered into an agreement
or understanding with others, you are instructed that the
[g]overnment need not show that the people involved had any
formal or written agreement nor that they specifically
discussed among themselves what the purpose or details of the
agreement would be or the means by which it would be
accomplished.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                  <b>(ii) Knowingly Unlawful Distribution</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government also established that "Mr. Bader <i>knew</i>
that the purpose of the agreement was to unlawfully distribute"
testosterone cypionate. <i></i><cite>Id. at 2178</cite> (emphasis added).
At trial, the jury was instructed that "[w]ith regard to
whether any distribution or possession with intent to
distribute testosterone cypionate by Mr. Bader was unlawful,"
it was to consider whether the government had shown "that Mr.
Bader either knew that he was distributing or possessing with
intent to distribute the testosterone cypionate without a valid
prescription by a medical practitioner or knew that the
prescription he was filling was issued without a valid medical
purpose." <i></i><cite>Id. at 2178-79</cite>. As Mr. Ruth and others
testified, Mr. Bader knew that he was distributing testosterone
to Peak Physique and other clinics for anti-aging and
body-building purposes. Furthermore, particularly in light of
Mr. Ruth's concession that <i>he</i> knew that anti-aging was
not a "valid medical purpose," <i></i><cite>id. at 2179</cite>, a
reasonable jury could have easily inferred that "a reasonable
pharmacist acting in good faith," <i></i><cite>id. at 2173</cite>, would
have known that these were unlawful uses. Thus, the government
also satisfied its burden of proof regarding element two of the
testosterone-conspiracy charge. Accordingly, construing the
evidence in the light most favorable to the government, a
reasonable jury could have convicted Mr. Bader of conspiracy to
distribute and to possess with the intent to distribute
testosterone cypionate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>C. <i>Prosecutorial Misconduct</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader claims that the government committed prosecutorial
misconduct when it prosecuted him for importation of HGH
contrary to law in spite of the district court's purported
pretrial ruling that the imported Genescience HGH was an API as
opposed to a finished drug. In so doing, he <span CLASS="page_no" data-cite="2012 bl 111342 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[**20]</span> argues that the
prosecution "intentionally misled th[e] jury to convict on an
unfounded legal basis" &mdash; that is, he was prosecuted on
the basis of "no legally cognizable evidence." Aplt. Reply Br.
at 15 (emphasis removed); <i>see United States v.</i>
<i>Farinella</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1AOK50003?jcsearch=558%20f%203d%20695&amp;summary=yes#jcite">558 F.3d 695</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1AOK50003?jcsearch=558%20f%203d%20695&amp;summary=yes#jcite">700-01</a> (7th Cir. 2009) (reversing
a defendant's conviction where the prosecutor committed
egregious misconduct in failing to present any evidence that
the defendant violated any federal law or FDA
regulation).<a HREF="#fn1700" name="fnref_fn1700">[fn17]</a> Because he raises it for the first time on
appeal, we
<span CLASS="page_no" data-cite="678 f 3d 885" data-cite-type="PrimaryFederalReporter" data-cite-pageno="885" data-primary-citation="678 F.3d 858">[*885]</span> 
review Mr. Bader's prosecutorial-misconduct contention for
plain error. <i>See, e.g., United States v. Sands</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XAC35S?jcsearch=968%20f%202d%201058&amp;summary=yes#jcite">968 F.2d 1058</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XAC35S?jcsearch=968%20f%202d%201058&amp;summary=yes#jcite">1063</a> (10th Cir. 1992).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "We use a two-step process when evaluating claims of
prosecutorial misconduct. First, we examine whether the conduct
was, in fact, improper. If we answer that question in the
affirmative, we must then determine whether it warrants
reversal." <i>United States v. Oberle</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XN5ACVQNB5G0?jcsearch=136%20f%203d%201414&amp;summary=yes#jcite">136 F.3d 1414</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XN5ACVQNB5G0?jcsearch=136%20f%203d%201414&amp;summary=yes#jcite">1421</a> (10th Cir. 1998). "When evaluating allegedly inappropriate
remarks of counsel for plain error, we must view the remarks in
the context of the entire trial." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XN5ACVQNB5G0?jcsearch=136%20F.3d%201414&amp;summary=yes#jcite">Id</a>.</i> (quoting
<i>Sands</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XAC35S?jcsearch=968%20f%202d%201058&amp;summary=yes#jcite">968 F.2d at 1063-64</a>) (internal quotation marks
omitted). Thus, "[t]he relevant question is whether the
prosecutors' comments `so infected the trial with unfairness as
to make the resulting conviction a denial of due process.'"
<i>Darden v. Wainwright</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBAC?jcsearch=477%20us%20168&amp;summary=yes#jcite">477 U.S. 168</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBAC?jcsearch=477%20us%20168&amp;summary=yes#jcite">181</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBAC?jcsearch=106%20supreme%20court%202464&amp;summary=yes#jcite">106 S.Ct. 2464</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBAC?jcsearch=91%20l%20ed%202d%20144&amp;summary=yes#jcite">91 L.Ed.2d 144</a> (1986) (quoting <i>Donnelly v.</i>
<i>DeChristoforo</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C8QF?jcsearch=416%20us%20637&amp;summary=yes#jcite">416 U.S. 637</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C8QF?jcsearch=416%20us%20637&amp;summary=yes#jcite">643</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C8QF?jcsearch=94%20supreme%20court%201868&amp;summary=yes#jcite">94 S.Ct. 1868</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5C8QF?jcsearch=40%20l%20ed%202d%20431&amp;summary=yes#jcite">40 L.Ed.2d 431</a> (1974)). Applying these standards to the facts
before us here, it is patent that Mr. Bader's allegations fall
short.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's argument fails, in part, because it is premised
upon a misreading of the record. Though Mr. Bader insists that
the district court concluded pretrial that "the imported [HGH]
undisputedly was API," Aplt. Opening Br. at 19, actually the
<i>court</i> made no such determination. As discussed above,
the <i>government</i> alleged that Mr. Bader had
"<i>represented</i>" to FDA officials that the Genescience
HGH was an "ingredient" in order to successfully (but
unlawfully) smuggle it into the United States. Aplt. App., Vol.
VI, Tr. at 1778 (emphasis added). If anything, the government's
allegation underscored its position that Mr. Bader had
facilitated the unlawful HGH importation through the use of
false statements, as charged in Count Sixteen of the Second
Superseding Indictment. <i>See</i> Aplee. App., Vol. IV,
at 1038. It certainly did not amount to a government concession
that the imported HGH was in fact an "API" as opposed to a
finished drug. Moreover, at no point did the <i>court</i>
conclude that the imported HGH was API; indeed, the
API/finished-drug distinction was exclusively reserved for jury
determination. Consequently, because neither the court nor the
government concluded or represented that the imported HGH was
an API, as opposed to a finished drug, the government's
argument that it was the latter (i.e., a finished drug) was
entirely proper. As such, Mr. Bader cannot satisfy even the
first prong of <i>Oberle's</i> two-step analysis with regard
to the government's allegedly impermissible statements
pertaining to finished HGH. <i>See Oberle</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XN5ACVQNB5G0?jcsearch=136%20f%203d%201414&amp;summary=yes#jcite">136 F.3d at 1421</a>. In sum, Mr. Bader has failed to offer any plausible
argument that the prosecution's actions were in any way
improper.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>D. <i>Constitutional and Estoppel <span CLASS="page_no" data-cite="2012 bl 111342 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[**21]</span> Claims</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>1. Entrapment by Estoppel and Right to Due Process</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Though the precise nature of Mr. Bader's claims are unclear, he
appears to contend
<span CLASS="page_no" data-cite="678 f 3d 886" data-cite-type="PrimaryFederalReporter" data-cite-pageno="886" data-primary-citation="678 F.3d 858">[*886]</span> 
that he was "entrapped" by the prosecution and by the
district court, in violation of his Fifth Amendment right to
due process. Specifically, Mr. Bader alleges that: (1) he
relied upon the Supreme Court's ruling in <i>Western</i>
<i>States</i> which held that the speech-related provisions of
the FDAMA were unconstitutional, as well as on a district
court's ruling that "compounded drugs" were not "new drugs"
subject to inspection by the FDA in <i>Medical Center Pharmacy</i>
<i>v. Gonzales</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X168EN8003?jcsearch=451%20f%20supp%202d%20854&amp;summary=yes#jcite">451 F.Supp.2d 854</a> (W.D.Tex. 2006), <i>vacated</i>
<i>in part by Medical Center Pharmacy v. Mukasey</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X198LUG003?jcsearch=536%20f%203d%20383&amp;summary=yes#jcite">536 F.3d 383</a> (5th Cir. 2008)<a HREF="#fn1800" name="fnref_fn1800">[fn18]</a>; (2) that the government nonetheless
prosecuted him under the FDAMA; and (3) that the district court
subsequently "used [the] FDAMA to justify [his] conviction,"
Aplt. Opening Br. at 37-38. Mr. Bader also suggests that
confusion in the legal landscape at the time that he engaged in
the conduct for which he was charged precludes his conviction
on due-process grounds. These claims are meritless.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "The defense of entrapment by estoppel is implicated where an
agent of the government affirmatively misleads a party as to
the state of the law and that party proceeds to act on the
misrepresentation so that criminal prosecution of the actor
implicates due process concerns under the Fifth and Fourteenth
Amendments." <i>United States v. Nichols</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3DKC6?jcsearch=21%20f%203d%201016&amp;summary=yes#jcite">21 F.3d 1016</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3DKC6?jcsearch=21%20f%203d%201016&amp;summary=yes#jcite">1018</a> (10th Cir. 1994). In order to establish an
entrapment-by-estoppel defense, a defendant must prove: (1)
that there was an "active misleading by a government agent";
(2) that the defendant actually relied upon the agent's
representation, which was "reasonable in light of the identity
of the agent, the point of law misrepresented, and the
substance of the misrepresentation"; and (3) that the
government agent is "one who is responsible for interpreting,
administering, or enforcing the law defining the offense."
<i>United States v. Apperson</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X151PB2003?jcsearch=441%20f%203d%201162&amp;summary=yes#jcite">441 F.3d 1162</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X151PB2003?jcsearch=441%20f%203d%201162&amp;summary=yes#jcite">1204-05</a>
(10th Cir. 2006) (quoting <i>United States v. Hardridge</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XFPDPD?jcsearch=379%20f%203d%201188&amp;summary=yes#jcite">379 F.3d 1188</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XFPDPD?jcsearch=379%20f%203d%201188&amp;summary=yes#jcite">1192</a> (10th Cir. 2004)) (internal quotation marks
omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To the extent that Mr. Bader premises his estoppel claim upon
federal court decisions, it fails at the outset. While this
circuit has yet to explicitly address whether a court's
<i>ruling</i> can give rise to a claim of estoppel,<a HREF="#fn1900" name="fnref_fn1900">[fn19]</a> the
law is clear that the offending party must be a
<span CLASS="page_no" data-cite="678 f 3d 887" data-cite-type="PrimaryFederalReporter" data-cite-pageno="887" data-primary-citation="678 F.3d 858">[*887]</span> 
"government <i>official or agency." United States v.</i>
<i>Gutierrez-Gonzalez</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X36AVG?jcsearch=184%20f%203d%201160&amp;summary=yes#jcite">184 F.3d 1160</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X36AVG?jcsearch=184%20f%203d%201160&amp;summary=yes#jcite">1167</a> (10th Cir. 1999)
(emphasis added). A court is neither an "official," nor for
purposes of making allegedly misleading declarations of law
would it customarily be understood to be an "agency." <i>Cf.</i>
<i>United States v. Manning</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18TUI2003?jcsearch=526%20f%203d%20611&amp;summary=yes#jcite">526 F.3d 611</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18TUI2003?jcsearch=526%20f%203d%20611&amp;summary=yes#jcite">617-18</a> (10th
Cir. 2008) (discussing the codified "judicial function
exception" to prosecution under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHS7C003?jcsearch=18%20usc%201001&amp;summary=yes#jcite">18 U.S.C. &sect; 1001</a>, which
makes the statute inapplicable to false statements made to the
court <i>in its judicial capacity</i>, rather than its
administrative capacity). Furthermore, courts cannot be said to
serve as an arm of the Executive Branch &mdash; indeed, it is
beyond peradventure that the separation of powers principles
embodied in our Constitution forbid them from operating as
such. Accordingly, any allegation <span CLASS="page_no" data-cite="2012 bl 111342 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[**22]</span> that a court, as an entity,
issued a decision inducing Mr. Bader to take a particular
action is not one upon which an estoppel claim may stand.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's remaining estoppel claim against the prosecution
fails at step one of the <i>Apperson</i> inquiry. <i>See</i>
<i>Apperson</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X151PB2003?jcsearch=441%20f%203d%201162&amp;summary=yes#jcite">441 F.3d at 1204</a>. Mr. Bader presents no evidence
that any government official made any sort of "active[ly]
misleading" statement with regard to the FDAMA; even if he had,
his argument would be based upon a faulty premise. As the
district court explained in its order denying Mr. Bader's
motion to dismiss, the FDAMA is "material to this case only as
a defense belonging to Mr. Bader." Aplee. App., Vol. IV,
at 1060 (emphasis removed).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the FDAMA, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 353a</a>(a), a licensed pharmacist
is <i>exempt</i> from federal liability where he compounds a
drug product "for an identified individual patient based on the
unsolicited receipt of a valid prescription order or a
notation," provided that certain conditions are met,
<i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a(a)&amp;summary=yes#jcite">id</a>.</i> The FDAMA therefore presents an affirmative
defense that Mr. Bader might have asserted, not a "charge" that
the government impermissibly sought. Thus, if anything, the
FDAMA could have worked to Mr. Bader's advantage &mdash; an
advantage that was precluded by Mr. Bader's repeated averments
that the FDAMA had no bearing upon his case. <i>See</i>
Aplee. App., Vol. I, Tr. at 1-2. As Mr. Bader offers no
evidence of "active misleading" &mdash; let alone evidence of
such conduct that might have prejudiced him at trial &mdash;
his entrapment-by-estoppel claim is without merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As for Mr. Bader's argument that "due process confusion
precluded [his] conviction," Aplt. Opening Br. at 39, although
it is not entirely clear, Mr. Bader appears to argue that the
confusion rendered in the wake of <i>Western States</i> and
<i>Medical Center Pharmacy</i> failed to place him on notice
that his "compounding" of HGH was subject to FDA oversight. In
this regard, Mr. Bader asserts that "[t]he courts told
<span CLASS="page_no" data-cite="678 f 3d 888" data-cite-type="PrimaryFederalReporter" data-cite-pageno="888" data-primary-citation="678 F.3d 858">[*888]</span> 
him [that] his pharmacy was compounding legally,"
<i></i><cite>id. at 37</cite>, and, based upon his survey of the legal
landscape, he "followed State law, the only law he knew to be
applicable," <i></i><cite>id. at 39</cite>. This argument is misguided.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With regard to <i>Western States</i>, by its terms, the
Court's decision merely invalidated the FDAMA's speech-related
provisions as they related to advertising; it did not address
the FDAMA's substantive exemptions and accompanying
restrictions with respect to compounding. <i>See</i>
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 366</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">377</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>. Therefore, Mr. Bader could not
have divined from the text of <i>Western States</i> that his
compounding activities were free from substantive FDA
regulation.<a HREF="#fn2000" name="fnref_fn2000">[fn20]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's decision in <i>Medical Center</i>
<i>Pharmacy</i> is also unavailing. In
<span CLASS="page_no" data-cite="678 f 3d 889" data-cite-type="PrimaryFederalReporter" data-cite-pageno="889" data-primary-citation="678 F.3d 858">[*889]</span> 
<i>Medical Center Pkarmacy</i>, the district court
concluded that "any drugs <i>created</i> through the
compounding process must be exempt from the new drug
definitions" of the FDCA. <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X168EN8003?jcsearch=451%20f%20supp%202d%20854&amp;summary=yes#jcite">451 F.Supp.2d at 864</a> (emphasis
added). Mr. Bader's convictions on appeal, however, pertain to:
(1) distribution of HGH for unauthorized use, in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e); (2) knowingly importing HGH into the
United States contrary to law, in violation of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a> and <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>; and (3) conspiracy with intent to
distribute and possess with intent to distribute testosterone
cypionate, in violation of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976D8003?jcsearch=21%20U.S.C.%20%20841(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 841</a>(a)(1),
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976D8003?jcsearch=21%20U.S.C.%20%20841(b)(1)(D)&amp;summary=yes#jcite">(b)(1)(D)</a>, and <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976DK003?jcsearch=21%20usc%20846&amp;summary=yes#jcite">21 U.S.C. &sect; 846</a>. Of these three <span CLASS="page_no" data-cite="2012 bl 111342 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[**23]</span> groups of
charges, only the second implicates new drug approval under the
FDA and, as discussed above, those charges concern only the
<i>imported</i> Genescience HGH as it existed <i>before</i>
it was compounded by College Pharmacy. Consequently,
<i>Medical Center Pharmacy</i> is inapposite.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, as the district court correctly concluded, Mr. Bader
misreads <i>Medical Center Pharmacy's</i>, actual holding. In
<i>Medical Center Pharmacy</i>, the court found that
subsections (a) and (c) of the FDAMA, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20usc%20353a&amp;summary=yes#jcite">21 U.S.C. &sect; 353a</a>,
were severable from the remainder of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a&amp;summary=yes#jcite">&sect; 353a</a>; consequently,
pharmacies were still obligated to comply with subsection (b)'s
requirements for "compounded drugs." <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X168EN8003?jcsearch=451%20f%20supp%202d%20854&amp;summary=yes#jcite">451 F.Supp.2d at 863</a>. In
other words, the court's decision can be read as concluding
that "only drugs compounded in compliance with the restrictions
set forth in [the] FDAMA fall outside [of] FDA regulation and
the NDA process." Aplt.App., Vol. II, at 559 (emphasis
removed).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, this "exemption for compounded drugs from the new
drug definition [was] limited to compounds which are made in
<i>reasonable quantities</i> upon receipt of a <i>valid</i>
<i>prescription for an individual patient</i> from a <i>licensed</i>
<i>practitioner.</i>" <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X168EN8003?jcsearch=451%20F.%20Supp.%202d%20854&amp;summary=yes#jcite">451 F.Supp.2d. at 863</a> (emphases added).
Indeed, the <i>Medical Center Pharmacy</i> court clarified
that "[d]rugs that are compounded in large quantities before a
prescription is received from a doctor do not fall within
[this] narrow exemption." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X168EN8003?jcsearch=451%20F.%20Supp.%202d%20854&amp;summary=yes#jcite">Id</a>.</i> It is clear from the
record that Mr. Bader's large-scale HGH compilation method fell
outside the protective scope of this exemption.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Specifically, Ms. Griffin's testimony regarding College
Pharmacy's "Somatropin prepackaged protocol" indicated that
College Pharmacy repackaged massive amounts of HGH as
Somatropin long before it received individual prescriptions,
and College Pharmacy's numerous advertisements extolling the
anti-aging and body-building benefits of HGH &mdash; in
conjunction with its promotion of the drug at trade shows for
those purposes &mdash; clearly
<span CLASS="page_no" data-cite="678 f 3d 890" data-cite-type="PrimaryFederalReporter" data-cite-pageno="890" data-primary-citation="678 F.3d 858">[*890]</span> 
suggested that College Pharmacy prepared and actively
marketed dosages of HGH on a massive scale. Thus, in sum,
<i>Medical Center Pharmacy</i> is inapposite for at least two
salient reasons: (1) it did not completely eviscerate the
compounded drug NDA requirements as Mr. Bader suggests; and (2)
its "limited exception" is not one under which Mr. Bader's
charged conduct would fall. Accordingly, Mr. Bader's reliance
upon <i>Medical Center Pharmacy</i> is misplaced, and the
case cannot support his illusory due-process claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>2. Sixth Amendment Claims</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader also argues that his Sixth Amendment rights were
violated: (1) when the district court purportedly limited his
ability to adequately cross-examine the government's "star
witness," FDA Agent Catherine Hermsen, in violation of the
Confrontation Clause; and (2) by "the [g]overnment's efforts to
keep out [evidence of] pharmacy practices," which prompted a
ruling by the court that allegedly hindered his ability to
raise a plausible <i>mens rea</i> defense at trial. Aplt.
Opening Br. at 43.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because Mr. Bader neglected to raise a Confrontation Clause
objection at trial, we review his first claim for plain error.
<i>See United States v. Pablo</i>, <cite>625 P.3d 1285</cite><span CLASS="page_no" data-cite="2012 bl 111342 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[**24]</span> , <cite>1291</cite> (10th
Cir. 2010). In so doing, the record reveals the absurdity of his
argument: the district court permitted Mr. Bader to extensively
cross-examine Agent Hermsen; the cross-examination fills
approximately 138 pages of transcript. Consequently, Mr. Bader
Confrontation Clause argument is wholly without merit and
cannot satisfy even the first prong of the plain-error
standard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's second argument is equally unavailing. Apparently,
Mr. Bader challenges the district court's setting of
"parameters as to what questions can be asked of witnesses,"
seemingly in reference to a warning that the court issued to
Mr. Bader's attorney: "if witnesses are repeatedly asked
questions about the state of the law[,] [the court] w[ill] be
compelled to admonish him before the jury." Aplt. App., Vol.
VII, Tr. at 2339; <i>see</i> Aplt. Opening Br. at 43. Mr.
Bader avers that this "ruling" deprived him of the ability to
introduce pertinent information regarding Colorado state
pharmacy regulations, consequently hindering his ability to
"disprove <i>mens rea</i>," Aplt. Opening Br. at 43, pursuant
to <i>Cheek v. United States</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=498%20us%20192&amp;summary=yes#jcite">498 U.S. 192</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=498%20us%20192&amp;summary=yes#jcite">202</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=111%20supreme%20court%20604&amp;summary=yes#jcite">111 S.Ct. 604</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=112%20l%20ed%202d%20617&amp;summary=yes#jcite">112 L.Ed.2d 617</a> (1991). This argument is
unpersuasive.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Cheek</i>, the Supreme Court noted that "forbidding the
jury to consider evidence that might negate willfulness would
raise a serious question under the Sixth Amendment's jury trial
provision." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=498%20U.S.%20192&amp;summary=yes#jcite">Id</a>.</i> at 203, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=111%20supreme%20court%20604&amp;summary=yes#jcite">111 S.Ct. 604</a>. <i>Cheek</i>,
however, was premised upon the district court's error in
instructing the jury that it was obligated to <i>completely</i>
<i>disregard evidence</i> that the defendant had a good faith
misunderstanding of the applicable tax laws. <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CBV7?jcsearch=498%20U.S.%20192&amp;summary=yes#jcite">Id</a>.</i> Here,
in contrast, the district court merely (and permissibly)
limited the <i>scope of defense counsel's questioning</i> on
account of counsel's repeated attempts to surreptitiously
introduce a legal definition of "compounding" that would favor
Mr. Bader. See Aplt. Trial Tr.App., Vol. IV, at 962 ("I'm . . .
going to instruct the jury that this witness' [s] understanding
of what compounding is[,] is not a legal definition of
compounding and therefore they should not understand it as
such."). This in no way ran afoul of the Sixth Amendment, nor
did it prevent Mr. Bader from otherwise attempting to introduce
a defense as to his understanding of the law at the time of the
allegedly illegal conduct. Accordingly, we conclude that
<i>Cheek</i> is inapposite,
<span CLASS="page_no" data-cite="678 f 3d 891" data-cite-type="PrimaryFederalReporter" data-cite-pageno="891" data-primary-citation="678 F.3d 858">[*891]</span> 
and that Mr. Bader's unsupported second claim is entirely
without merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>E. <i>Alleged Evidentiary Errors</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alternatively, Mr. Bader alleges that he should at least be
afforded a new trial on account of various evidentiary
objections that the government made and that the district court
ruled upon. First, Mr. Bader asserts that the government
impermissibly and excessively objected to much of the evidence
that the defense offered, particularly that relating to the
FDA's approval of the HGH shipments as an API, College Pharmacy
employees' understanding of the meaning of "compounding," FDA
import alerts distinguishing between API and finished HGH, and
test results regarding the HGH that was seized from College
Pharmacy. Mr. Bader apparently claims that the government's
frequent objections <span CLASS="page_no" data-cite="2012 bl 111342 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[**25]</span> somehow amounted to prosecutorial
misconduct. Because he failed to challenge these objections at
trial, we review for plain error. <i>Sands</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XAC35S?jcsearch=968%20f%202d%201058&amp;summary=yes#jcite">968 F.2d at 1063</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is clear that there was nothing "improper" about the
government's objections, nor has Mr. Bader fashioned any
argument as to how we might construe them as such. <i>See</i>
<i>Oberle</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XN5ACVQNB5G0?jcsearch=136%20f%203d%201414&amp;summary=yes#jcite">136 F.3d at 1421</a>. Each of the objections that Mr.
Bader contests was grounded in the Federal Rules of Evidence,
and each was entirely consistent with the government's
overarching theory of the case &mdash; <i>viz.</i>, that the
imported HGH was a "finished drug," not an API. In raising
these objections, the government merely upheld its obligation
to zealously advocate for its position, and the district court
certainly did not clearly or obviously err by permitting the
objections.<a HREF="#fn2100" name="fnref_fn2100">[fn21]</a> Accordingly, we need not further consider Mr.
Bader's unsubstantiated allegations regarding this matter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, Mr. Bader argues that the district court erred in
sustaining the government's objections and in "refus[ing] to
allow the defendant the same latitude" as the government with
regard to the introduction of evidence. Aplt. Opening Br.
at 44. However, Mr. Bader offers absolutely no explanation as to
how the district court abused its discretion in ruling on the
government's objections, nor does he establish that each of the
allegedly impermissible government objections was actually
sustained in the first place. <i>See</i> Aplt. Opening Br.
at 42-43. Consequently, he has left us with no basis upon which we
might discern error with the district court's evidentiary
rulings.'
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, Mr. Bader provides no meaningful support for his
conclusory assertion that the court "allow[ed] the [g]overnment
to offer evidence on critical issues" while depriving him of an
opportunity to do the same. <i></i><cite>Id. at 44</cite>. Specifically,
Mr. Bader contends that the court allowed the government to
"impermissibl[y] use . . . its rejected compounding
definition," while rejecting Mr. Bader's
<span CLASS="page_no" data-cite="678 f 3d 892" data-cite-type="PrimaryFederalReporter" data-cite-pageno="892" data-primary-citation="678 F.3d 858">[*892]</span> 
own compounding definition. <i><cite>Id</cite>.</i> However, Mr. Bader
points to nothing in the record evincing the government's
impermissible use of a compounding definition that the court
rejected. Moreover, even assuming <i>arguendo</i> that there
was some foundation in the record for his assertion, Mr. Bader
fails to explain how the court's alleged "rejection" of his own
compounding definition was erroneous.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader also appears to argue that the court abused its
discretion in refusing to admit the government's pretrial
concession that "their case was gutted" with regard to Mr.
Bader's HGH claims if the court were to adopt the compounding
definition that he proffered.<a HREF="#fn2200" name="fnref_fn2200">[fn22]</a> Aplt.App., Vol. VIII, Tr.
at 2570. The government, in opposing Mr. Bader's request,
argued that its prior "admission" should be excluded under
Federal Rule of Evidence <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X135KKK003?jcsearch=Fed%20R%20Evid%20403&amp;summary=yes#jcite">403</a>, particularly since the alleged
admission arose out of the government's pretrial motion to
dismiss &mdash; a motion that it had no occasion to pursue
because the district court favorably shifted its position on
the need to instruct the jury concerning Colorado's compounding
laws. <i></i><cite>Id. at 2571</cite>. Mr. Bader presents no argument as
to how the district court's decision <span CLASS="page_no" data-cite="2012 bl 111342 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[**26]</span> to deny Mr. Bader's
request to admit the government's statement constitutes an
abuse of discretion; indeed, it was entirely possible &mdash;
and, in fact, probable &mdash; that the admission of the
statement would have confused the jury and proved to be
unfairly prejudicial to the government. Accordingly, because
Mr. Bader has provided no persuasive argument pertaining to any
of the alleged evidentiary errors, he has presented no basis
upon which we might grant him a new trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<b>F. <i>Forfeiture</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Mr. Bader challenges the district court's $4.8 million
forfeiture order,
<span CLASS="page_no" data-cite="678 f 3d 893" data-cite-type="PrimaryFederalReporter" data-cite-pageno="893" data-primary-citation="678 F.3d 858">[*893]</span> 
renewing his argument that the calculated amount was
improperly based upon "aggregated [HGH] sales" rather than
properly "limit[ed] . . . to proceeds `constitut[ing]' or
`derived' from a crime." Aplt. Opening Br. at 67 (third
alteration in original). Additionally, Mr. Bader argues that
the court erroneously failed to reduce the forfeiture amount to
account for (1) the HGH seized and retained by the government,
and (2) the HGH attributable to the counts for which Mr. Bader
was acquitted.<a HREF="#fn2300" name="fnref_fn2300">[fn23]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Forfeiture is an element of the sentence imposed following
conviction. . . ." <i>Libretti v. United States</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCQ5?jcsearch=516%20us%2029&amp;summary=yes#jcite">516 U.S. 29</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCQ5?jcsearch=516%20us%2029&amp;summary=yes#jcite">38-39</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCQ5?jcsearch=116%20supreme%20court%20356&amp;summary=yes#jcite">116 S.Ct. 356</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CCQ5?jcsearch=133%20l%20ed%202d%20271&amp;summary=yes#jcite">133 L.Ed.2d 271</a> (1995) (emphasis
removed); <i>see United States v. Wittig</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1Q6L6UDT182?jcsearch=575%20f%203d%201085&amp;summary=yes#jcite">575 F.3d 1085</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1Q6L6UDT182?jcsearch=575%20f%203d%201085&amp;summary=yes#jcite">1096</a> (10th Cir. 2009) ("Double jeopardy does not apply to the
forfeiture findings because forfeiture is a component of a
sentence rather than an offense for which the defendants were
tried." (internal quotation marks omitted)). Consequently, we
review the district court's forfeiture order as we would any
other sentencing determination &mdash; that is, we review its
legal conclusions de novo and its factual findings for clear
error. <i>See, e.g., United States v. Olguin</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FHVBI003?jcsearch=643%20f%203d%20384&amp;summary=yes#jcite">643 F.3d 384</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FHVBI003?jcsearch=643%20f%203d%20384&amp;summary=yes#jcite">395</a> (5th Cir. 2011) (observing that, in reviewing a
district court's forfeiture order, the "court reviews the
district court's findings of fact under the clearly erroneous
standard of review, and the question of whether those facts
constitute legally proper forfeiture de novo."); <i>United</i>
<i>States v. Browne</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17S3VO003?jcsearch=505%20f%203d%201229&amp;summary=yes#jcite">505 F.3d 1229</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17S3VO003?jcsearch=505%20f%203d%201229&amp;summary=yes#jcite">1278</a> (11th Cir. 2007) ("We
review <i>de novo</i> the district court's legal conclusions
regarding forfeiture and the court's findings of fact for clear
error." (quoting <i>United States v. Pucke</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CPI3?jcsearch=350%20f%203d%201137&amp;summary=yes#jcite">350 F.3d 1137</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CPI3?jcsearch=350%20f%203d%201137&amp;summary=yes#jcite">1153</a> (11th Cir. 2003)) (internal quotation marks
omitted)); <i>cf. United States v. McGinty</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1DJJO2003?jcsearch=610%20f%203d%201242&amp;summary=yes#jcite">610 F.3d 1242</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1DJJO2003?jcsearch=610%20f%203d%201242&amp;summary=yes#jcite">1245</a> (10th Cir. 2010) (concluding that we apply de novo
review to our <i>legal</i> interpretation of federal
forfeiture <i>statutes</i>). A forfeiture judgment must be
supported by a preponderance of the evidence. <i>See United</i>
<i>States v. Dieter</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3F3HQ?jcsearch=198%20f%203d%201284&amp;summary=yes#jcite">198 F.3d 1284</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3F3HQ?jcsearch=198%20f%203d%201284&amp;summary=yes#jcite">1289</a> (11th Cir. 1999)
("[T]he preponderance standard is most consistent with the
notion that <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=21%20U.S.C.%20853(a)(2)&amp;summary=yes#jcite">section 853(a)(2)</a> forfeiture is a matter of
sentencing."); Stefan D. Cassella, <i>Asset Forfeiture Law in</i>
<i>the United States</i> <cite>&sect; 15-3(d)</cite>, at 480 (2007)
[hereinafter <i>Asset Forfeiture Law</i>] ("Because
forfeiture is part of sentencing, the Government's burden is to
establish the nexus between the property and the offense by a
preponderance of the evidence, not beyond a reasonable
doubt.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader seemingly seeks to reassert here the argument that he
set forth in his post-trial motion to set aside the jury's
forfeiture verdict &mdash; <i>viz.</i>, that "the calculation
of proceeds based on gross HGH sales, instead of net sales, was
improper." Aplee. App., <span CLASS="page_no" data-cite="2012 bl 111342 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[**27]</span> Vol. IV, at 1273; <i>see </i><cite>id.
at 1189-1212</cite> (Def.'s Mot. to Set Aside Special Forfeiture Verdict
Under Rule 29(C) and Opp'n to Gov't's Mot. for Forfeiture,
filed Mar. 5, 2010). In his motion before the district court,
Mr. Bader relied primarily upon the Supreme Court's ruling in
<i>United States v. Santos</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VIJ8003?jcsearch=553%20us%20507&amp;summary=yes#jcite">553 U.S. 507</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VIJ8003?jcsearch=128%20supreme%20court%202020&amp;summary=yes#jcite">128 S.Ct. 2020</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VIJ8003?jcsearch=170%20l%20ed%202d%20912&amp;summary=yes#jcite">170 L.Ed.2d 912</a> (2008), where he argued that only the "profits"
that he derived from the allegedly illegal conduct, as opposed
to the "gross receipts," could be included for purposes of the
forfeiture calculation, <i>see</i> Aplee. App., Vol. IV,
at 1201-02 (internal quotation
<span CLASS="page_no" data-cite="678 f 3d 894" data-cite-type="PrimaryFederalReporter" data-cite-pageno="894" data-primary-citation="678 F.3d 858">[*894]</span> 
marks omitted). In his opening brief, however, Mr. Bader
devotes only a single sentence to this argument, baldly
asserting &mdash; with no explanation &mdash; that the
forfeiture verdict was based upon improperly "aggregated [HGH]
sales" rather than being restricted to "proceeds
`constitut[ing] or `derived' from a crime." Aplt. Opening Br.
at 67 (second alteration in original). That is not enough. Mr.
Bader has waived this argument on appeal. <i>See, e.g., Kabba</i>
<i>v. Mukasey</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1965VM003?jcsearch=530%20f%203d%201239&amp;summary=yes#jcite">530 F.3d 1239</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1965VM003?jcsearch=530%20f%203d%201239&amp;summary=yes#jcite">1248</a> (10th Cir. 2008)
("[B]ecause the issue was insufficiently raised in [the
party's] opening brief, we agree that it has been waived.");
<i>Becker v. Kroll</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17AQ60003?jcsearch=494%20f%203d%20904&amp;summary=yes#jcite">494 F.3d 904</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17AQ60003?jcsearch=494%20f%203d%20904&amp;summary=yes#jcite">913</a> n. 6 (10th
Cir. 2007) ("An issue or argument insufficiently raised in the
opening brief is deemed waived."); <i>Gaither v. Aetna Life</i>
<i>Ins. Co.</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XGFNJN?jcsearch=394%20f%203d%20792&amp;summary=yes#jcite">394 F.3d 792</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XGFNJN?jcsearch=394%20f%203d%20792&amp;summary=yes#jcite">810</a> (10th Cir. 2004) (Murphy, J.,
dissenting) ("It is well-settled in this Circuit that an issue
listed, but not argued in the opening brief is waived.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In any event, unlike the present case, <i>Santos</i> involved
whether the term "proceeds" meant "profits" &mdash; as opposed
to gross receipts &mdash; under the federal money-laundering
statute. <i>See</i> <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VIJ8003?jcsearch=553%20us%20507&amp;summary=yes#jcite">553 U.S. at 513-14</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X18VIJ8003?jcsearch=128%20supreme%20court%202020&amp;summary=yes#jcite">128 S.Ct. 2020</a>;
<i>see also</i> <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHSRO003?jcsearch=18%20U.S.C.%20%201956(a)(1)(A)(i)&amp;summary=yes#jcite">18 U.S.C. &sect; 1956</a>(a)(1)(A)(i). As we
recently observed, "<i>Santos</i> . . . caused considerable
disagreement and confusion among the circuit courts of appeal,"
<i>Thornburgh</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEI003?jcsearch=645%20f%203d%201197&amp;summary=yes#jcite">645 F.3d at 1208</a>, with the result that
"the <i>Santos</i> decision has been interpreted by lower
courts in many different ways," <i>Fishman</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEK003?jcsearch=645%20f%203d%201175&amp;summary=yes#jcite">645 F.3d at 1193</a>. We "therefore confined it to its factual setting, and
conclude[d] that `proceeds' means `profits' for the purpose of
the money laundering statute <i>only</i> where an illegal
gambling operation is involved." <i>Fishman</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1FGSEK003?jcsearch=645%20f%203d%201175&amp;summary=yes#jcite">645 F.3d at 1193-94</a>. Mr. Bader's reliance on <i>Santos</i> is therefore
misplaced, as his convictions pertain neither to the federal
money-laundering statute nor to an illegal gambling operation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Bader's remaining two claims &mdash; that the court erred
in failing to exclude the amount of HGH (1) that the government
seized and kept, and (2) that was attributable to the counts
upon which he was acquitted &mdash; are also waived on account
of his utter failure to explain or in any way substantiate his
allegations, including with citation to legal authority.<a HREF="#fn2400" name="fnref_fn2400">[fn24]</a>
<i>See, e.g., United States v. Pursley</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1BHAN8003?jcsearch=577%20f%203d%201204&amp;summary=yes#jcite">577 F.3d 1204</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1BHAN8003?jcsearch=577%20f%203d%201204&amp;summary=yes#jcite">1231</a> n. 17 (10th Cir. 2009) ("[A]lthough Mr. Pursley alluded to
the ex parte issue in his appellate brief, that skeletal
reference does not present a cognizable issue for appellate
review."); <i>Bronson v. Swensen</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17J5FO003?jcsearch=500%20f%203d%201099&amp;summary=yes#jcite">500 F.3d 1099</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17J5FO003?jcsearch=500%20f%203d%201099&amp;summary=yes#jcite">1104</a>
(10th Cir. 2007). The latter argument about acquitted counts,
however, prompts us to consider a separate issue: Because we
reverse Mr. Bader's convictions for knowingly facilitating the
sale of illegally imported HGH and conspiring to commit that
offense (i.e., Counts Seventeen and One, respectively), we must
consider the impact of that action on the district <span CLASS="page_no" data-cite="2012 bl 111342 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[**28]</span> court's
forfeiture order.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There must be a nexus between the property forfeited and <i>an</i>
<i>offense of conviction</i> that authorizes forfeiture. <i>See</i>
<i>United States v. Bornfield</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3BT2J?jcsearch=145%20f%203d%201123&amp;summary=yes#jcite">145 F.3d 1123</a>,
<span CLASS="page_no" data-cite="678 f 3d 895" data-cite-type="PrimaryFederalReporter" data-cite-pageno="895" data-primary-citation="678 F.3d 858">[*895]</span> 
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3BT2J?jcsearch=1137&amp;summary=yes#jcite">1137</a> n. 8 (10th Cir. 1998) (dismissing the government's
suggestion that both bank accounts at issue were tied to the
structuring count because if that were true, "the government
would have no basis for forfeiture of either account as
[defendant] was not convicted of the structuring charge");
<i>see also United States v. Capoccia</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17MHV0003?jcsearch=503%20f%203d%20103&amp;summary=yes#jcite">503 F.3d 103</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17MHV0003?jcsearch=503%20f%203d%20103&amp;summary=yes#jcite">116</a>
(2d Cir. 2007) ("The violation on which the forfeiture is based
must be the specific violations of which Capoccia was
convicted. . . ."); <i>United States v. Hasson</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6BK77?jcsearch=333%20f%203d%201264&amp;summary=yes#jcite">333 F.3d 1264</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6BK77?jcsearch=333%20f%203d%201264&amp;summary=yes#jcite">1279</a> n. 19 (11th Cir. 2003) ("We do not mean to imply that
a court could impose a forfeiture order based on a money
laundering offense with which the defendant was not charged or
for which he was acquitted.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, because we reverse Mr. Bader's convictions of
conspiring to knowingly facilitate the sale of illegally
imported HGH and knowingly facilitating the sale of illegally
imported HGH, the forfeiture judgment against Mr. Bader cannot
rest on his violation of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20usc%20545&amp;summary=yes#jcite">18 U.S.C. &sect; 545</a>. <i>See Asset</i>
<i>Forfeiture Law, <cite>supra</cite></i>, <cite>&sect; 15-3(a)</cite>, at 476 ("[I]f the
conviction that supported a forfeiture is reversed on appeal,
the forfeiture &mdash; along with all other aspects of the
defendant's sentence for that offense &mdash; must be reversed
as well."). Ordinarily, such violations would trigger
forfeiture under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHS72003?jcsearch=18%20U.S.C.%20%20981(a)(1)(C)&amp;summary=yes#jcite">18 U.S.C. &sect; 981</a>(a)(1)(C) (noting that
"property is subject to forfeiture to the United States" where
it "constitutes or is derived from proceeds traceable to a
violation of section . . . <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRS4003?jcsearch=18%20U.S.C.%20%20545&amp;summary=yes#jcite">545</a> . . ., or a conspiracy to commit
such offense"). Yet, significantly, the district court's
analysis focused primarily on this <cite>&sect; 545-related</cite> path of
forfeiture, in particular in rejecting Mr. Bader's contention
that "the $4.8 million forfeiture verdict is inconsistent with
evidence that reveals a smaller amount is attributable to
illegal HGH sales." Aplee. App., Vol. IV, at 1275.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the court's analysis revealed, there was ample evidence of
unlawful HGH sales to support the $4.8 million figure by a
preponderance of the evidence. Among other things, the
government presented College Pharmacy's own sales records
detailing a total of approximately $4.7 million in sales of
imported HGH. This sales log was corroborated by Catherine
Hermsen, a Special Agent ("SA") with the FDA Office of Criminal
Investigations, who testified that the log detailed College
Pharmacy's Somatropin sales from September 13, 2004 to March
30, 2007. SA Hermsen also explained that she verified this
figure through information retrieved from College Pharmacy's
computer server, as well as through her own review of checks
that the FDA had subpoenaed. These records revealed that
College Pharmacy also had issued additional payments to Bradley
Blum, which resulted in a total of $4.8 million estimated
proceeds attributable to Mr. Bader's HGH-related crimes.
<i>See <cite>id</cite>.</i>, Vol. II, Tr. at 441 ("We came up with $4.8
million."). Additionally, as the district court observed in its
disposition of Mr. Bader's motion to set aside the forfeiture
order, SA Hermsen explicitly noted that this "$4.8 million
figure <span CLASS="page_no" data-cite="2012 bl 111342 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[**29]</span> <i>excluded</i> College Pharmacy's lawful sales of
commercially-produced, NDA[-]approved HGH, such as Saizen and
Norditropin." <i><cite>Id</cite>.</i>, Vol. IV, at 1275 (emphasis
altered); <i>see <cite>id</cite>.</i>, Vol. II, at 440 (SA Hermsen
testifying about a separate log that exclusively recorded the
sales of the illegally imported HGH).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To be sure, the district court correctly suggested that the
Second Superseding Indictment charged Mr. Bader with violating
other statutes that, in appropriate circumstances, may support
a forfeiture judgment.<a HREF="#fn2500" name="fnref_fn2500">[fn25]</a> <i>See <cite>id</cite>.</i>, Vol. IV, at 1273
(noting
<span CLASS="page_no" data-cite="678 f 3d 896" data-cite-type="PrimaryFederalReporter" data-cite-pageno="896" data-primary-citation="678 F.3d 858">[*896]</span> 
that "[e]ach of the counts of conviction in this case
give[s] rise to a claim for forfeiture, albeit through varying
statutory routes"). Furthermore, the district court's
instructions and verdict form &mdash; to which Mr. Bader did
not lodge an objection &mdash; did not ask the jury to attach
its forfeiture finding to any particular counts of the Second
Superseding Indictment. Instead, these documents only obliged
the jury to determine whether Mr. Bader had "obtained [as
proceeds] directly or indirectly <i>as a result of the</i>
<i>crime(s) for which</i> [it] found [him] guilty" "the sum of
$4.8 million." Aplt.App., Vol. IV, at 1196. (Jury Verdict Form,
dated Feb. 2, 2010) (emphasis added); <i>accord <cite>id</cite>.</i>, Vol.
VIII, at 2749-50 (Jury Instruction No. 41); <i>cf.</i> Aplee.
App., Vol. IV, at 1040 (seeking "[a] sum of money equal to
$4,800,000 in United States Currency, representing the amount
of proceeds obtained as a result of the offenses in <i>Counts</i>
<i>One through Seventeen, and Nineteen</i>" &mdash;
<i>viz.</i>, proceeds obtained pursuant to the charges of
knowing facilitation of the sale of illegally imported HGH,
conspiracy to do so, mail fraud, distribution of HGH, and
conspiracy to distribute and to possess with the intent to
distribute testosterone cypionate (emphasis added)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Yet, given the current posture of this case &mdash; involving
our reversal of the <cite>&sect; 545-related</cite> HGH counts &mdash; we are
reluctant to speak definitively regarding the precise amount
(if any) of proceeds that properly may be attributed to the
other (i.e., non <cite>&sect; 545</cite>) counts of the Second Superseding
Indictment for purposes of adjudging the forfeiture
amount.<a HREF="#fn2600" name="fnref_fn2600">[fn26]</a> <i>Cf. Asset Forfeiture Law, <cite>supra</cite></i>,
<cite>&sect; 15-3(a)</cite>, at 476-77 ("[A] defendant may be acquitted on one
offense and yet be convicted on another that gives rise to the
forfeiture of the same property. In that case, the forfeiture
would survive the acquittal (or the reversal of the conviction)
on the first offense because it would have an independent
basis."). First, our analysis might be rendered of little or no
effect, if the government elects upon remand to retry Mr. Bader
on Counts One and Seventeen (i.e., the <cite>&sect; 545-related</cite>
counts) and he is convicted again. Then, <cite>&sect; 545</cite> would again
be a viable basis on which to rest a forfeiture award.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  And, second, we do not have the benefit of the parties'
briefing on the implications of our reversal of the
<cite>&sect; 545-related</cite> counts with regard to the precise amount of the
forfeiture judgment that is legally authorized based on the
remaining convictions. Of course, that is not surprising
because it is only through this opinion that we effectuate our
reversals. However, the reversals do raise serious questions.
As noted, the district court relied in its forfeiture
<span CLASS="page_no" data-cite="678 f 3d 897" data-cite-type="PrimaryFederalReporter" data-cite-pageno="897" data-primary-citation="678 F.3d 858">[*897]</span> 
analysis on the testimony <span CLASS="page_no" data-cite="2012 bl 111342 p 30" data-cite-type="Bloomberg" data-cite-pageno="30" data-primary-citation="">[**30]</span> of SA Hermsen concerning the
aggregate amount of the HGH sales during a time period
beginning shortly after the start of the charged
<cite>&sect; 545-related</cite> conspiracy and concluding at the end of the
conspiracy. Agent Hermsen testified that those sales totaled
$4.8 million.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Let us assume, however, that Mr. Bader <i>only</i> may be
held accountable in monetary forfeiture under the Second
Superseding Indictment for <i>all</i> of the unlawful HGH
sales identified by the government, because of his
<cite>&sect; 545-related</cite> conspiracy charge, which sweeps broadly enough to
encompasses those sales. <i>See, e.g., Capoccia</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X17MHV0003?jcsearch=503%20f%203d%20103&amp;summary=yes#jcite">503 F.3d at 117-18</a> ("Where the conviction itself is for executing a
scheme, <i>engaging in a conspiracy</i>, or conducting a
racketeering enterprise, the government need only establish
that the forfeited assets have the `requisite nexus' to that
scheme, conspiracy, or enterprise." (emphasis added) (citation
omitted) (quoting Fed.R.Crim.P. <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X135KD6003?jcsearch=Fed.%20R.%20Crim.%20P.%2032.2(b)(1)&amp;summary=yes#jcite">32.2</a>(b)(1))); <i>Asset</i>
<i>Forfeiture Law, <cite>supra</cite></i>, <cite>&sect; 15-3(a)</cite>, at 477 ("[I]f the
defendant is convicted of an <i>over-arching conspiracy</i>
offense, he may be ordered to forfeit all property involved in
the conspiracy, including property involved in substantive
conduct that is not charged in the indictment or on which the
defendant was acquitted." (emphasis added)). Put another way,
let us assume that proceeds from <i>uncharged</i> discrete
acts of facilitating the sale of illegally imported HGH may
<i>not</i> be considered in determining the total monetary
proceeds subject to forfeiture. <i>See Asset Forfeiture Law,</i>
<i><cite>supra</cite></i>, <cite>&sect; 15-3(b)</cite>, at 478 ("Because forfeiture is
part of the defendant's sentence for <i>committing a given</i>
<i>offense</i>, the criminal forfeiture is limited to the
property involved in <i>that</i> offense." (emphases added)).
In this event, even assuming that some of the remaining counts
of conviction (e.g., involving <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e) or
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976DK003?jcsearch=21%20usc%20846&amp;summary=yes#jcite">21 U.S.C. &sect; 846</a>) would yield forfeitable proceeds, what would
be the proper amount of those proceeds? The district court's
analysis does not offer an answer, nor have the parties
addressed the matter before us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We are disinclined to answer such complex questions without
input from the parties or the district court. The district
court is better equipped to entertain the parties' arguments;
if necessary, consider additional evidence; and to resolve such
questions in the first instance. In sum, given our reversal of
Mr. Bader's <cite>&sect; 545-related</cite> convictions, we think it the
prudent course to allow the district court in the first
instance to speak to the precise amount (if any) of the
forfeiture judgment that is legally authorized in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             <b>III. CONCLUSION</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, we AFFIRM Mr. Bader's convictions
for discrete distributions of HGH (Counts Twelve through
Fifteen, and Count Twenty), and conspiracy to distribute and to
possess with intent to distribute testosterone cypionate, i.e.,
anabolic steroids (Count Nineteen); REVERSE his convictions for
knowingly facilitating the sale of illegally imported HGH and
for conspiring to do so (Counts Seventeen and One,
respectively); and REMAND Mr. Bader's case to the district
court with instructions to VACATE its judgment and sentence,
and to conduct further proceedings consistent with this
opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> <i>See generally Thompson v. W. States Med. Ctr.</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. 357</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">360-61</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=152%20l%20ed%202d%20563&amp;summary=yes#jcite">152 L.Ed.2d 563</a> (2002)
("Drug compounding is a process by which a pharmacist or doctor
combines, mixes, or alters ingredients to create a medication
tailored to the needs of an individual patient. Compounding is
typically used to prepare medications that are not commercially
available, such as medication for a patient who is allergic to
an ingredient in a mass-produced product."); 1 James T.
O'Reilly, <i>Food and Drug Administration</i> &sect; 13:74,
at 194 (Supp. 2011) [hereinafter <i>Food and Drug</i>]
("Congress could have, but did not ever affirmatively define
the term `compounding.' . . . There is no single,
commonly-accepted industry or common definition of the term
`compounding,' and the definition does not necessarily exclude
simple repackaging.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> "Under the Federal Food, Drug, and Cosmetic Act (FDCA), a
drug manufacturer may not market a new drug before first
submitting a new drug application (NDA) to the FDA and
receiving the agency's approval." <i>Wyeth v. Levine</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">1219</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ALNB4003?jcsearch=173%20l%20ed%202d%2051&amp;summary=yes#jcite">173 L.Ed.2d 51</a> (2009) (Breyer,
J., concurring) (citing <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(a)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An NDA must contain, among other things, the labeling
  proposed to be used for such drug, full reports of
  investigations which have been made to show whether or
  not such drug is safe for use and whether such drug is
  effective in use, and a discussion of why the benefits
  exceed the risks [of the drug] under the conditions
  stated in the labeling.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1ALNB4003?jcsearch=129%20S.%20Ct.%201187&amp;summary=yes#jcite">Id</a>.</i> (alteration in original) (citations omitted)
(quoting <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1) and
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XMJ52K003?jcsearch=21%20C.F.R.%20%20314.50(d)(5)(viii)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.50</a>(d)(5)(viii) (2008)) (internal quotation marks omitted).
In order to receive FDA approval, a new drug must be "safe for
use under the conditions prescribed, recommended, or suggested
in the proposed labeling thereof," there must be "substantial
evidence that the drug will have the effect it purports or is
represented to have under the conditions of use prescribed,
recommended, or suggested in the proposed labeling thereof,"
and the drug's proposed labeling must not be "false or
misleading in any particular." <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(d); <i>see</i>
<i>also</i> Aplee. App., Vol. 1, Tr. at 17 (Test, of Jason Woo)
("The new drug approval process refers to the requirement that
any article that's intended for use in the diagnosis,
treatment, prevention, mitigation or cure of a disease for
humans or animals has to be presented to the . . . FDA[] for
review for safety and efficacy before it can be marketed
legally.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The district court's error may have partially derived
from its misplaced reliance upon <i>Hedgpeth v. Pulido</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1A5QQI003?jcsearch=555%20us%2057&amp;summary=yes#jcite">555 U.S. 57</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1A5QQI003?jcsearch=129%20supreme%20court%20530&amp;summary=yes#jcite">129 S.Ct. 530</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1A5QQI003?jcsearch=172%20l%20ed%202d%20388&amp;summary=yes#jcite">172 L.Ed.2d 388</a> (2008) (per
curiam). While the district court was correct that
<i>Hedgpeth</i> directs courts to consider "whether [a] flaw
in the [jury] instructions `had substantial and injurious
effect or influence in determining the jury's verdict,'"
<i></i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1A5QQI003?jcsearch=555%20U.S.%2057&amp;summary=yes#jcite">id. at 58</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1A5QQI003?jcsearch=129%20supreme%20court%20530&amp;summary=yes#jcite">129 S.Ct. 530</a> (quoting <i>Brecht v.</i>
<i>Abrahamson</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CC8R?jcsearch=507%20us%20619&amp;summary=yes#jcite">507 U.S. 619</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CC8R?jcsearch=507%20us%20619&amp;summary=yes#jcite">623</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CC8R?jcsearch=113%20supreme%20court%201710&amp;summary=yes#jcite">113 S.Ct. 1710</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CC8R?jcsearch=123%20l%20ed%202d%20353&amp;summary=yes#jcite">123 L.Ed.2d 353</a> (1993)), its holding pertains to whether purported
instructional errors are "structural" in nature for purposes of
collateral review in a habeas proceeding. As Mr. Bader's case
involves neither a claim of structural error nor a collateral
attack in a habeas proceeding, <i>Hedgpeth</i> is
inapposite.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The Second Superseding Indictment explained that "[t]he
FDA has never approved any [HGH] manufactured in or imported
from China for lawful use in the United States." Aplee. App.,
Vol. IV, at 1025. No where does the indictment suggest,
however, that an individual may be held criminally liable for
illegally importing an API that was manufactured at a
<i>facility</i> lacking FDA registration.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> The district court apparently relied upon <i>United</i>
<i>States v. Urbano</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1B1LRM003?jcsearch=563%20f%203d%201150&amp;summary=yes#jcite">563 F.3d 1150</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1B1LRM003?jcsearch=563%20f%203d%201150&amp;summary=yes#jcite">1155</a> (10th Cir. 2009), for
the proposition that we must assume that the jury "did not vote
to convict on a theory for which no evidence existed." Aplee.
App., Vol. IV, at 1262. In that case, however, we held only
that "this court generally assumes jurors follow jury
instructions." <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1B1LRM003?jcsearch=563%20f%203d%201150&amp;summary=yes#jcite">563 F.3d at 1155</a>. Where, as in <i>Urbano</i>,
the erroneous instruction is entirely "extraneous" to the
charges upon which a defendant is indicted &mdash; such that if
the jury followed the erroneous instruction, a conviction would
not result &mdash; any error is necessarily harmless. <i>See</i>
<i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1B1LRM003?jcsearch=563%20F.3d%201150&amp;summary=yes#jcite">id</a>.</i> Here, in contrast, the court's erroneous instruction
was far from "extraneous"; on the contrary, it provided an
<i>alternative</i> basis upon which the jury could convict
Mr. Bader in the event that it found that he had not imported a
"finished drug." Moreover, the government <i>did</i> present
evidence supporting this alternative, API-based theory at
trial. As such, <i>Urbano</i> offers no support for the
district court's position.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> In reaching this disposition, however, we pause to note
the possibility that Mr. Bader may be reprosecuted on these
counts. Upon remand, in the event that he is reprosecuted, it
will be important for the parties to furnish the court with
appropriate instructions, reflective of the applicable law, so
as to provide the jury with adequate guidance regarding the
"finished drug" versus "API" distinction. The district court
was correct when it represented to the jury that "[t]here is no
definition under the law for the term `finished drug,'" Aplt.
Trial Tr.App., Vol. VIII, at 2169; however, we do not operate
on a blank slate. While the law is far from clear, we endeavor
to outline here the relevant precedent to which the parties and
the court should look in defining these terms upon remand.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the Supreme Court has explained, "[t]he active ingredients
in most prescription drugs constitute less than 10% of the
product; inactive `excipients' (such as coatings, binders, and
capsules) constitute the rest." <i>United States v. Generix</i>
<i>Drug Corp.</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=460%20us%20453&amp;summary=yes#jcite">460 U.S. 453</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=460%20us%20453&amp;summary=yes#jcite">454</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=103%20supreme%20court%201298&amp;summary=yes#jcite">103 S.Ct. 1298</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=75%20l%20ed%202d%20198&amp;summary=yes#jcite">75 L.Ed.2d 198</a> (1983). A "complete product[]," therefore, consists of
"active ingredients and excipients together." <i></i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=460%20U.S.%20453&amp;summary=yes#jcite">Id.
at 461</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=103%20supreme%20court%201298&amp;summary=yes#jcite">103 S.Ct. 1298</a>. Thus, the district court was correct when
it instructed the jury that a finished drug product &mdash; as
opposed to an API &mdash; is often in "finished dosage form;
for example, a tablet, capsule, or solution." Aplt. Trial
Tr.App., Vol. VIII, at 2169.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Much of the law concerning the finished-drug versus API
distinction is grounded in the recent methamphetamine epidemic.
Pursuant to <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976II003?jcsearch=21%20U.S.C.%20%20971(c)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 971</a>(c)(1), for example, the DEA
"may order the suspension of any importation or exportation of
a listed chemical . . . on the ground that the chemical may be
diverted to the clandestine manufacture of a controlled
substance." <i>PDK Labs., Inc. v. DEA</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1471AU003?jcsearch=438%20f%203d%201184&amp;summary=yes#jcite">438 F.3d 1184</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1471AU003?jcsearch=438%20f%203d%201184&amp;summary=yes#jcite">1186</a>
(D.C. Cir. 2006) (quoting Pub.L. No. <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=USACTS%20100-690&amp;summary=yes#jcite">100-690</a>, tit. VI,
<cite>&sect; 6053(a)</cite>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/1?citation=102%20stat%204312&amp;summary=yes#jcite">102 Stat. 4312</a> (1988)) (internal quotation marks
omitted). One of these "listed chemical[s]" &mdash; ephedrine
&mdash; "is an active ingredient in over-the-counter
medications for the treatment of asthma and nasal congestion.
Ephedrine is also used in the illicit production of
methamphetamine, a controlled substance." <i>PDK Labs., Inc.</i>
<i>v. DEA</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CT2T?jcsearch=362%20f%203d%20786&amp;summary=yes#jcite">362 F.3d 786</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CT2T?jcsearch=362%20f%203d%20786&amp;summary=yes#jcite">789</a> (D.C. Cir. 2004). It has therefore
fallen upon the courts to determine whether the DEA can act
pursuant to <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976II003?jcsearch=21%20U.S.C.%20%20971(c)(1)&amp;summary=yes#jcite">&sect; 971(c)(1)</a> in order to divert a pharmacy's
finished drug &mdash; as opposed to the raw API that it imports
&mdash; from the hands of methamphetamine producers who seek to
buy (or purchase) the medication from retail stores. In so
doing, courts have offered at least a cursory explanation of
the production process: pharmacies "purchase[] raw, bulk
ephedrine from foreign companies, <i>combine[] the chemical</i>
<i>with other active agents</i>, and produce[] a <i>finished</i>
<i>product</i> in tablet form, packaged in bottles or blister
packs." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X6CT2T?jcsearch=362%20F.3d%20786&amp;summary=yes#jcite">Id</a>.</i> (emphases added). Thus, at least in the
methamphetamine context, an API is a raw product that is
<i>combined</i> with other active ingredients to produce a
"finished drug product" that is ready for public consumption.
In other words, a finished drug is a final, patient-ready drug
that consists of one or more APIs and, most likely, one or more
"excipients." <i>See Generix</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=460%20us%20453&amp;summary=yes#jcite">460 U.S. at 461</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5CADT?jcsearch=103%20supreme%20court%201298&amp;summary=yes#jcite">103 S.Ct. 1298</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, this Court has also weighed in on the API/finished-drug
distinction. In <i>Pharmanex v. Shalala</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20f%203d%201151&amp;summary=yes#jcite">221 F.3d 1151</a>
(10th Cir. 2000), the FDA challenged the district court's
decision to enjoin an FDA administrative decision that
concluded that Cholestin &mdash; a product intended to promote
healthy cholesterol levels &mdash; was not a "dietary
supplement" that was exempt from FDA regulation. "The district
court," we explained, "based its decision on the determination
that [the relevant statute] refer[ed] unambiguously to
<i>finished drug products</i>, rather than their
<i>individual constituents." </i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20F.3d%201151&amp;summary=yes#jcite">Id. at 1153</a> (emphases
added). On appeal, the FDA argued that the applicable statute
was "properly understood to contemplate active ingredients as
well as finished drug products." <i></i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20F.3d%201151&amp;summary=yes#jcite">Id. at 1154</a>
(footnotes omitted). Our role, therefore, was to "determine
whether Congress unambiguously manifested its intent to exclude
only finished drug products (rather than ingredients) from the
definition of dietary supplement." <i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20F.3d%201151&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In so doing, we noted that the term "`[a]ctive ingredient'
means `any <i>component</i> that is intended to furnish
pharmacological activity or other direct effect.'" <i></i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20F.3d%201151&amp;summary=yes#jcite">Id.
at 1154</a> n. 3 (emphasis added) (quoting <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XMJ4GO003?jcsearch=21%20C.F.R.%20210.3(b)(7)&amp;summary=yes#jcite">21 C.F.R. 210.3</a>(b)(7)),
while a "`[d]rug product'" &mdash; a term that we analogized to
"finished drug product" &mdash; "is defined as a `finished
dosage form . . . that contains a <i>drug substance</i>,
generally, but not necessarily, <i>in association with one or</i>
<i>more drug ingredients.</i>'" <i></i><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3ITG7?jcsearch=221%20F.3d%201151&amp;summary=yes#jcite">Id. at 1154</a> n. 4
(emphases added) (quoting <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XMJ52G003?jcsearch=21%20C.F.R.%20314.3(b)&amp;summary=yes#jcite">21 C.F.R. 314.3</a>(b)). These
definitions &mdash; promulgated by the FDA itself &mdash; are
certainly less than clear. At the very least, however, they
provide a rudimentary foundation regarding the interrelation
between the two terms: an API is a medicinally active
"component" that is associated with additional "drug
substance[s]" to form a "finished product" available in
individual doses. <i>See id.</i> at 1154 n. 3-4. These
definitions, in conjunction with the aforementioned case law,
should inform the district court's jury instructions in the
event that Mr. Bader is retried.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Mr. Bader presented this argument for the first time in
his post-<i>trial</i> motion for judgment of acquittal.
<i>See</i> Aplee. App., Vol. IV, at 1257. His objection at
trial, in contrast, merely sought to include a definition of
the term "prescription" in Instruction No. 12. <i>See</i>
Aplt.App., Vol. VIII, Tr. at 2699.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> In addressing a sufficiency-of-the-evidence challenge, a
panel of the Ninth Circuit construed the statute as having a
similar breadth. <i>See United States v. Hunter</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1G0MSM003?jcsearch=445%20f%20appx%20998&amp;summary=yes#jcite">445 Fed.Appx. 998</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1G0MSM003?jcsearch=445%20f%20appx%20998&amp;summary=yes#jcite">1000-01</a> (9th Cir. 2011) ("Because Hunter's sales
of HGH were for a use in humans that was not approved by the
FDA and were <i>not</i> pursuant to a physician's
prescription, those sales violated <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e)."
(emphasis added)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Mr. Bader also avers that the government's reliance upon
these advertisements runs afoul of the First Amendment in light
of the Supreme Court's decision in <i>Western States.</i> In
<i>Western States</i>, the Court invalidated several
restrictions of the Food and Drug Administration Modernization
Act of 1997 ("FDAMA") on advertising of compounded drugs on the
ground that they constituted unconstitutional restrictions on
commercial speech. <i>See</i> <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 360</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG4UTQ?jcsearch=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>. As the government points out, however, Mr. Bader's First
Amendment rights were not at issue in the instant case, and
there is absolutely nothing in <i>Western States</i> that
bars the government from relying upon a defendant's commercial
advertisements as evidence that he sought to distribute HGH or
any other compounded drug for an unauthorized use in violation
of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e). Thus, any First Amendment argument
by Mr. Bader predicated on <i>Western States</i> is without
merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> Generally, a new drug must be approved by the FDA
through an NDA, under which it is approved for specific uses
&mdash; i.e., to treat certain conditions. Any use of the drug
other than that in the approved labeling is considered an
"off-label" use of the drug. Aplee. App., Vol. I, Tr. at 20-21.
For most drugs, these off-label uses are entirely legal, and
physicians may proceed to prescribe the drug for other
purposes. As Dr. Woo explained, however, this is not the case
with HGH; due to congressional concerns with HGH abuse,
off-label prescriptions of HGH are uniformly illegal.
<i><cite>Id</cite>.</i> This is evident from the plain language of
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">&sect; 333(e)</a>, which holds a party liable for <i>any</i> use of HGH
that has not been expressly "authorized by the Secretary of
Health and Human Services." <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> Mr. Bader also appears to advance two related arguments:
that he must be acquitted of the HGH <cite>&sect; 545-related</cite> charges
(1) because the government conceded that the imported HGH was
an API, rather than "finished" drug, at pretrial proceedings;
and (2) because "four-fifths of the [HGH] counts" &mdash; i.e.,
the twenty-three HGH distribution counts involving
prescriptions to minors which were validly issued by physicians
&mdash; were deemed unsupported by sufficient evidence and
dismissed post-trial. Aplt. Opening Br. at 19. Mr. Bader also
makes a third argument in his reply brief, asserting that his
conviction for importation of HGH cannot stand because he was
acquitted of "receiving contraband" lacking NDA approval in
Count Sixteen, which necessitates a finding that the imported
HGH was not "finished." Aplt. Reply Br. at 3. These arguments
are without merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, with regard to the government's allegedly inconsistent
pretrial position, Mr. Bader misinterprets the government's
statements. The government merely asserted pretrial that Mr.
Bader had falsely "represented" that the HGH was an
"ingredient" in order to import it into the United States, in
accordance with its theory that Mr. Bader received smuggled HGH
on the basis of false statements, <i>see</i> Aplt.App., Vol.
VI, Tr. at 1778 ("That's how it [i.e., HGH] was
<i>represented</i>, your Honor, for compounding purposes as
an ingredient." (emphasis added)); at no point did the
government indicate that the imported HGH was actually an API.
Moreover, at no point did the <i>court "note</i>[]," Aptt.
Opening Br. at 19, that the imported HGH was an API; on the
contrary, the court observed that the Genescience API was
released for importation by FDA inspectors on the basis of Mr.
Bader's allegedly <i>false representation</i> that the
Genescience HGH was an API as opposed to a finished drug,
<i>see</i> Aplt.App., Vol. VI, Tr. at 1962. Second, the
court's subsequent decision to vacate Mr. Bader's convictions
for distribution of HGH to minors hinged upon the government's
inability to prove that those HGH prescriptions had been
<i>dispensed</i> in the United States for improper purposes;
the dismissals had absolutely nothing to do with the
<i>importation</i> of that HGH.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because Mr. Bader cursorily asserts his third argument for the
first time in his reply brief, we need not consider it in the
first place. <i>See, e.g., Stump v. Gates</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3IQUA?jcsearch=211%20f%203d%20527&amp;summary=yes#jcite">211 F.3d 527</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3IQUA?jcsearch=211%20f%203d%20527&amp;summary=yes#jcite">533</a> (10th Cir. 2000) ("This court does not ordinarily review
issues raised for the first time in a reply brief. . . . It
robs the appellee of the opportunity to demonstrate that the
record does not support an appellant's . . . assertions. . . .").
However, even if we were to do so, we would conclude that
it is without merit. Specifically, the jury's decision to
acquit Mr. Bader of receiving stolen goods under Count Sixteen
of the Second Superseding Indictment had no bearing upon his
<cite>&sect; 545-related</cite> convictions. Count Sixteen primarily turned
upon <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRRU003?jcsearch=18%20usc%20542&amp;summary=yes#jcite">18 U.S.C. &sect; 542</a>, which relates to the entry of
merchandise into the United States by means of false
statements. Aplee. App., Vol. IV, at 1038-39; <i>see</i>
Aplt. Trial Tr.App., Vol. VIII, at 2173 (Jury Instruction
No. 26). A reasonable jury could have found that Mr. Bader was
not guilty of having knowingly facilitated the importation of
HGH into the United States <i>through false statements</i>
to the FDA (i.e., statements indicating that the HGH was an
API in order to gain import approval), yet simultaneously
concluded that Mr. Bader was nevertheless guilty of knowingly
facilitating the sale of an illegally imported finished drug
&mdash; even if the importation of this finished drug was not
facilitated through false representations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> While we conclude that the government presented
sufficient evidence that the imported Genescience HGH was a
"finished drug," the government offered us little help in
reaching this conclusion. Though the government baldly asserts
that Mr. Bader "directed employees of College Pharmacy to
repackage the Genescience [HGH] into smaller vials labeled with
College Pharmacy boxes and information" for sale as
"Somatropin," without ever "add[ing] ingredients to, or
remov[ing] anything from, the product itself," Aplee. Br.
at 21-22, it fails to point to <i>any</i> excerpts from the
record that support these sweeping statements. We remind
counsel that is not this Court's job to "sift through the
record to find support" for the government's arguments, and its
failure to "direct us to the location in the voluminous record
where we [might] find support for their [arguments]" has
resulted in the unnecessary expenditure of valuable judicial
resources. <i>Phillips v. James</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12OGQ8003?jcsearch=422%20f%203d%201075&amp;summary=yes#jcite">422 F.3d 1075</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12OGQ8003?jcsearch=422%20f%203d%201075&amp;summary=yes#jcite">1081</a>
(10th Cir. 2005).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> In most material respects, the district court's
instruction accurately reflects the elements of conspiracy
under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRNC003?jcsearch=18%20usc%20371&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>, which we have repeatedly
articulated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To convict a defendant of conspiracy under
  <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRNC003?jcsearch=18%20usc%20371&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>, the government must prove that: (1) there
  was an agreement to violate the law, (2) the defendant
  knew the essential objective of the conspiracy, (3)
  the defendant knowingly and voluntarily participated
  in the conspiracy, (4) an overt act was committed in
  furtherance of the conspiracy, and (5) the
  coconspirators were interdependent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1G2F7Q003?jcsearch=654%20f%203d%201104&amp;summary=yes#jcite">654 F.3d at 1115</a> (quoting <i>United States v.</i>
<i>Bedford</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X19DR2S003?jcsearch=536%20f%203d%201148&amp;summary=yes#jcite">536 F.3d 1148</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X19DR2S003?jcsearch=536%20f%203d%201148&amp;summary=yes#jcite">1156</a> (10th Cir. 2008)) (internal
quotation marks omitted). We pause, however, to observe that
the district court equated the "overt act" element with the
accomplishment of a "substantial step" toward the completion of
the crime. Yet, as we have noted, an "overt act" and a
"substantial step" are distinct concepts in the law and the
latter <i>necessarily</i> contemplates a threshold or
baseline action of greater magnitude than the former. <i>See</i>
<i>United States v. Irving</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1GPR52003?jcsearch=665%20f%203d%201184&amp;summary=yes#jcite">665 F.3d 1184</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1GPR52003?jcsearch=665%20f%203d%201184&amp;summary=yes#jcite">1198</a> n. 14 (10th
Cir. 2011) ("In conspiracy law, given the existence of an
unlawful agreement, `virtually any act will satisfy the overt
act requirement.' In other words, the overt act need not
necessarily be substantial." (citation omitted) (quoting Wayne
R. LaFave, <i>Substantive Criminal Law</i> <cite>&sect; 12.2(b)</cite>,
at 627 (4th ed. 2003))). Thus, theoretically, the district court's
instruction could be interpreted as having placed a greater
burden of proof on the government than mandated by <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEHRNC003?jcsearch=18%20U.S.C.%20%20371&amp;summary=yes#jcite">&sect; 371</a>.
However, the government did not object to any possible error in
this instruction and therefore was bound by it. <i>See, e.g.,</i>
<i>United States v. Williams</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEQ9KT?jcsearch=376%20f%203d%201048&amp;summary=yes#jcite">376 F.3d 1048</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEQ9KT?jcsearch=376%20f%203d%201048&amp;summary=yes#jcite">1051</a> (10th
Cir. 2004) ("The law of the case is applied to hold the
government to the burden of proving each element of a crime as
set out in a jury instruction to which it failed to object,
even if the unchallenged jury instruction goes beyond the
criminal statute's requirements."). In any event, given the
nature of Mr. Bader's specific challenges, we have no need to
address this matter further.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> The government did elicit testimony from College
Pharmacy pharmacists indicating that patient-prescription
histories that detailed the dispensing practices of these two
doctor; were readily available on a College Pharmacy computer
system. <i>See</i> Aplee. App., Vol. I, Tr. at 108-10 (Test,
of Teresa Weisenbach); <i>see also </i><cite>id. at 49-51</cite> (Test, of
Frieda Martin). However, Mr. Bader points to record evidence
tending to establish that these physicians ceased doing
business with College Pharmacy in 2003. <i>See</i> Aplt.
Opening Br. at 59-60. In its answer brief, the government does
not appear to dispute this fact. This is significant, because
by its own admission, Mr. Bader only had access to that
computer system as Pharmacy Manager beginning in July 2005.
<i>See</i> Aplt.App., Vol. V, at 1421 (Gov't's Resp. to
Def.'s Mot. for J. of Acquittal and in the Alternative for New
Trial, filed Apr. 2, 2010). Therefore, we have difficulty
seeing how the testimony of the government witnesses indicating
that the two physicians' patient-prescription histories would
have been available on the College Pharmacy computer advances
the government's cause. Nonetheless, as noted above, the
evidence concerning the two physicians was only a small part of
the inculpatory picture painted by the government concerning
the charge of conspiracy to unlawfully distribute and possess
with the intent to distribute testosterone cypionate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1500" name="fn1500">[fn15]</a></span> Once again, Mr. Bader apparently objects to the
government's reliance upon these advertisements on First
Amendment grounds. As we explained <i><cite>supra</cite></i>, however,
this argument is without merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1600" name="fn1600">[fn16]</a></span> Mr. Bader contends that College Pharmacy's website
advertisement contains "no discussion of body-building";
instead, he avers, it merely references a "report from a
congressionally-chartered medical institute stating that
testosterone is useful for men who suffer from hypogonadism,"
which is an "age-related medical condition." Aplt. Opening Br.
at 62-63. First, to the extent that College Pharmacy's web page
contains such a report reference, as best we can tell, it does
not do so on the face of College Pharmacy's homepage or in the
advertisement that appears at the top of that homepage. Second,
Mr. Bader's contention that the advertisement was not geared
toward "body building" is clearly refuted by the overtly
muscular male image that the advertisement prominently
displays. A reasonable jury presented with this image could
have easily concluded that the advertisement was geared toward
<i>muscle, not medicine</i>, particularly in light of Mr.
Ruth's statement that it was developed to promote the product's
use for the former.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1700" name="fn1700">[fn17]</a></span> Though Mr. Bader relies heavily upon <i>Farinella</i>
in support of his poorly presented prosecutorial-misconduct
argument, that case is largely inapposite. In
<i>Farinella</i>, the Seventh Circuit reversed the
defendant's convictions for wire fraud and introducing into
interstate commerce a misbranded food with intent to defraud
and mislead where the prosecutor failed to present <i>any</i>
evidence that the defendant's changing of a product's "best
when purchased by" date constituted a "misbranding" of food or
otherwise violated federal law or FDA regulations.
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1AOK50003?jcsearch=558%20f%203d%20695&amp;summary=yes#jcite">558 F.3d at 700-01</a>. In the present case, in contrast, Mr. Bader's <cite>&sect; 545</cite>
illegal importation charge was predicated upon
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OQ003?jcsearch=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>, which expressly forbids the importation of any "new drug"
absent FDA approval. <i>See</i> Aplee. App., Vol. IV,
at 1037-38. Thus, so long as the government presented evidence
that the Genescience HGH was in all material respects a "new
drug" &mdash; i.e., a finished drug as opposed to an API
&mdash; it presented a theory upon which a reasonable jury
could convict Mr. Bader of illegally importing HGH. And the
government in fact presented ample evidence on this point.
Consequently, this is a far cry from the government's failure
to present <i>any</i> evidence that the defendant violated
any law or regulation in <i>Farinella</i>; indeed, but for
the fact that <i>Farinella</i> involved products that fall
within the purview of the FDA's regulatory scheme, it bears no
resemblance to the present case. <i>Farinella</i> lends no
support to Mr. Bader's argument.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1800" name="fn1800">[fn18]</a></span> The Fifth Circuit partially reversed the district
court's decision in <i>Medical Center Pharmacy</i>, having
concluded that compounded drugs were not uniformly exempt from
the FDA's "new drug" approval requirements &mdash; in other
words, to be exempted, compounded drugs must still comply with
the conditions set forth in the FDAMA, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OK003?jcsearch=21%20usc%20353&amp;summary=yes#jcite">21 U.S.C. &sect; 353</a>.
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X198LUG003?jcsearch=536%20f%203d%20383&amp;summary=yes#jcite">536 F.3d at 405-06</a>. Mr. Bader notes that he has not cited
<i>Gonzales</i> "as a statement of current law." Rule 28(j)
Resp. Ltr. at 2 (dated Mar. 18, 2011). Instead, Mr. Bader
appears to rely upon the Texas district court's decision
because it was issued during the time period that he allegedly
committed the crimes for which he was charged. However, Mr.
Bader was indicted for conduct beginning in April 2004, and the
district court published <i>Gonzales</i> in August 2006.
Thus, even if the court's decision in <i>Gonzales</i> could
justify his conduct post-August 2006, it does not apply to Mr.
Bader's conduct between 2004 and 2006. <i>See</i> Aplt.App.,
Vol. II, at 558-59 (Op. &amp; Order Granting, In Part, Mot. for
Reconsideration, and Reserving Remainder, dated July 23, 2009);
Aplt. Opening Br. Add. 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1900" name="fn1900">[fn19]</a></span> In summarily rejecting Mr. Bader's claim that the
Supreme Court's decision in <i>Western States</i> had led him
to believe that the "FDAMA was unconstitutional in its entirety
and that College Pharmacy's operations fell outside of FDA
oversight," the district court stated that "judicial findings
or advisements do not typically give rise to the doctrine of
entrapment by estoppel." Aplee. App., Vol. IV, at 1058 (Op.
&amp; Order Den. Remaining Mots., dated Nov. 12, 2009).
However, the cases that the district court cites are
specifically premised upon the notion that a <i>state</i>
court judge cannot plausibly offer an interpretation of
<i>federal</i> law upon which a defendant may rely. <i>See</i>
<i>United States v. Stults</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XB0RFQNB5G0?jcsearch=137%20f%20appx%20179&amp;summary=yes#jcite">137 Fed. Appx. 179</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XB0RFQNB5G0?jcsearch=137%20f%20appx%20179&amp;summary=yes#jcite">184</a> (10th
Cir. 2005) (holding that defendant did not present a plausible
claim of entrapment by estoppel where it was based upon the
representations of a <i>state</i> probation officer and a
<i>state</i> judge pertaining to his conviction under
<i>federal</i> law); <i>United States v. Etheridge</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5443G?jcsearch=932%20f%202d%20318&amp;summary=yes#jcite">932 F.2d 318</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X5443G?jcsearch=932%20f%202d%20318&amp;summary=yes#jcite">321</a> (4th Cir. 1991) (noting that no defense of
entrapment by estoppel could be established where "the
government that advises and the government that prosecutes are
not the same") (quoting <i>United States v. Bruscantini</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3UUNP?jcsearch=761%20f%202d%20640&amp;summary=yes#jcite">761 F.2d 640</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3UUNP?jcsearch=761%20f%202d%20640&amp;summary=yes#jcite">641-42</a> (11th Cir. 1985)) (internal quotation marks
omitted); <i>see also Bruscantini</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3UUNP?jcsearch=761%20f%202d%20640&amp;summary=yes#jcite">761 F.2d at 641-42</a>
(explaining that "the entrapment problem is different" where
state officials provided the legal interpretation upon which
the defendant relied, but his conviction was based upon federal
law), <i>abrogated on other grounds by United States v.</i>
<i>Fernandez</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X2PO0T?jcsearch=234%20f%203d%201345&amp;summary=yes#jcite">234 F.3d 1345</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X2PO0T?jcsearch=234%20f%203d%201345&amp;summary=yes#jcite">1347</a> n. 2 (11th Cir. 2000). As
Mr. Bader asserts no such reliance upon a state court decision,
these cases do not provide an answer for the question posed by
Mr. Bader's argument.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2000" name="fn2000">[fn20]</a></span> To be sure, because of the unique procedural posture of
<i>Western States</i>, the FDA suggested in certain policy
guidance that the decision also effectively invalidated the
FDAMA's substantive provisions. <i>See</i> Compliance Policy
Guidance ("CPG") <cite>&sect; 460.200</cite>. The FDA described the situation
this way:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court affirmed the 9th Circuit Court of
  Appeals decision that found <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a&amp;summary=yes#jcite">section 503A</a> of the [FDCA,
  added by the FDAMA] invalid in its entirety because it
  contained unconstitutional restrictions on commercial
  speech (i.e., prohibitions on soliciting prescriptions
  for and advertising specific compounded drugs). The
  Court did not rule on, and therefore left in place,
  the 9th Circuit's holding that the unconstitutional
  restrictions on commercial speech could not be severed
  from the rest of <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a&amp;summary=yes#jcite">section 503A</a>. Accordingly, all of
  <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a&amp;summary=yes#jcite">section 503A</a> is now invalid.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><cite>Id</cite>.</i> However, the overarching premise of this policy
guidance was that, generally, the FDA had maintained some
degree of regulatory authority over pharmacy compounding both
before <i>Western States</i> &mdash; as ultimately defined
and restricted by the FDAMA, <i>cf. Food and Drug, <cite>supra</cite></i>,
<cite>&sect; 13.74</cite>, at 194 (noting that "no FDAMA-described safe
harbor would have been necessary if the FDA indeed [previously]
lacked the power to regulate compounded drugs") &mdash; and
after <i>Western States.</i> However, following <i>Western</i>
<i>States</i> the agency "recognize[d] the need for immediate
guidance on what <i>types</i> of compounding might be subject
to enforcement action under current law," and it indicated that
its principal focus would be on the situation "when the scope
and nature of a pharmacy's activities raise the kinds of
concerns normally associated with a drug manufacturer." CPG
<cite>&sect; 460.200</cite> (emphasis added). In that regard, among other
things, the FDA would consider whether the pharmacy was
involved in "[c]ompounding of drugs in anticipation of
receiving prescriptions, <i>except in very limited</i>
<i>quantities</i> in relation to the amounts of drugs compounded
after receiving valid prescriptions." <i><cite>Id</cite>.</i> (emphasis
added). As the Third Circuit noted:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [W]e agree that the FDA's reliance on the apparent
  volume of compounding is a reasonable means of
  determining whether that pharmacy is compounding in
  the regular course of its business of dispensing or
  selling drugs or devices at retail. Indeed, were we to
  adopt Wedgewood's view that the volume of compounding
  is irrelevant, much of the FDCA would become a
  nullity. If a pharmacy could compound an unlimited
  quantity of drugs, supposedly in anticipation of
  individual prescriptions, then it could essentially
  act as a commercial drug manufacturer and totally
  circumvent the approval requirements of the FDCA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Wedgewood Vill. Pharmacy, Inc. v. United States</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12OBO0003?jcsearch=421%20f%203d%20263&amp;summary=yes#jcite">421 F.3d 263</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X12OBO0003?jcsearch=421%20f%203d%20263&amp;summary=yes#jcite">274</a> (3d Cir. 2005) (internal quotation marks omitted);
accord Food and Drug, <i><cite>supra</cite></i>, <cite>&sect; 13:74</cite>, at 13-95
(3d ed. 2007). As we further explicate <i>infra</i>, Mr. Bader
and College Pharmacy were involved in the large-scale
preparation and marketing of dosages of HGH. Consequently, even
taking into account the FDA's arguably broad reading of the
substantive impact of <i>Western States</i>, Mr. Bader still
would have had fair warning &mdash; as it related at least to
his pharmacy business &mdash; of the possibility of FDA
regulatory oversight.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, viewed from another perspective, Mr. Bader has
repeatedly discounted the effect of this specific policy
provision &mdash; CPG <cite>&sect; 460.200</cite> &mdash; noting that it is
"nonbinding" and "not law or proper for instruction." Aplt.
Opening Br. at 7 n. 11; <i>see </i><cite>id. at 38</cite> (noting that "the
[compliance policy guidance] CPG admittedly is not law and may
not be instructed"). In this regard, he has cited
<i>Professionals and Patients for Customized Care v.</i>
<i>Shalala</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X4NH0F?jcsearch=56%20f%203d%20592&amp;summary=yes#jcite">56 F.3d 592</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X4NH0F?jcsearch=56%20f%203d%20592&amp;summary=yes#jcite">597</a>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X4NH0F?jcsearch=56%20f%203d%20592&amp;summary=yes#jcite">602</a> (5th Cir. 1995) (holding
that Compliance Guidance Manual provision relating to whether
pharmacies were engaged in drug manufacturing did not establish
"binding norms"). As a consequence, Mr. Bader is not
well-situated now to contend that this policy guidance had
placed a gloss on <i>Western States</i> that muddied the
waters concerning the FDA's substantive regulatory authority
over compounding. Furthermore, insofar as Mr. Bader's argument
focuses on whether the FDAMA's specific substantive provisions
related to compounding remained viable after <i>Western</i>
<i>States</i>, Mr. Bader would be hard-pressed to claim prejudice
resulting from any lack of notice concerning the state of the
law because he has expressly declined to avail himself of a
statutory FDAMA defense to justify his compounding activities.
<i>See, e.g.</i>, Aplee. Supp.App., Vol. I, at 1-2. In light
of his large-scale preparation and marketing of HGH doses this
declination is not entirely surprising. <i>See</i>
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a(a)(2)&amp;summary=yes#jcite">21 U.S.C. &sect; 353a</a>(a)(2); Aplee Br. at 40 ("Defendant's waiver [of a
FDAMA compounding defense] is consistent with the knowledge
that, even if the FDAMA was viable, the evidence did not
support its applicability to the instant case.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2100" name="fn2100">[fn21]</a></span> Mr. Bader concludes his evidentiary allegations against
the prosecution with the assertion that the government went "so
far as to intimidate witnesses not to say [that] College
compounded the [HGH]." Aplt. Opening Br. at 44. Stacy Griffin,
a College Pharmacy employee, did testify on cross that she
"remember[ed] [the government] getting upset with [her]" when
she referred to the College Pharmacy process as "compounding"
HGH. Aplt.App., Vol. VII, Tr. at 2375. Her statement, however,
falls far short of evidence that the government "intimidated" a
witness. <i>Cf. United States v. Morrison</i>, <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3U6OC?jcsearch=535%20f%202d%20223&amp;summary=yes#jcite">535 F.2d 223</a>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X3U6OC?jcsearch=535%20f%202d%20223&amp;summary=yes#jcite">227</a> (3d Cir. 1976) (noting that "[t]he actions of the prosecutor
in his repeated warnings [that the potential witness could be
prosecuted for drug and perjury charges] which culminated in a
highly intimidating personal interview were completely
unnecessary" and required reversal of defendant's conviction).
Accordingly, we do not credit Mr. Bader's witness-intimidation
argument.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2200" name="fn2200">[fn22]</a></span> Prior to trial, the government filed a motion asking the
district court to reconsider its decision to issue a jury
instruction on the Colorado definition of "compounding" and, in
the alternative, to dismiss counts one through fifteen,
seventeen, and twenty through forty-three of the Second
Superseding Indictment &mdash; i.e., those counts related to
conspiracy to facilitate the sale of illegally imported HGH,
distribution of HGH, facilitating the sale of illegally
imported HGH, possession with intent to distribute HGH, and
distribution of HGH to minors. In that motion, the government
conceded that "the [c]ourt's proposed definition of compounding
<i>substantially undermine[d</i>] the [g]overnment's theory
of criminal liability in the [HGH] related counts," and
therefore asked that, in the interest of judicial economy,
<i>the HGH counts be dismissed</i> in the event that the
court still planned to instruct the jury as to the definition
of compounding under Colorado law. Aplt.App., Vol. II, at 495
(Gov't's Mot. to Reconsider &amp; in the Alternative Mot. to
Dismiss, dated Apr. 14, 2009) (emphasis added). In disposing of
that motion, the court confirmed that it would instruct the
jury according to Colorado law, but amended that instruction
slightly such that the jury would "be instructed in two phases:
(i) that `compounding' is defined according to the terms of
Colorado law as set forth in [Colo.Rev.Stat.]
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XG5696003?jcsearch=Colo.%20Rev.%20Stat.%20%2012-22-102(6)&amp;summary=yes#jcite">&sect; 12-22-102(6)</a>; and (ii) that a drug that is otherwise
`compounded' according to that definition may still be subject
to NDA requirements and other regulatory burdens if it runs
afoul of the terms of the [FDA's 2002] CPG/FDAMA." <i></i><cite>Id.
at 566</cite>. Observing that the government's position might be
"different" on the basis of the court's conclusion that "both
the state definition of `compounding' and the provisions of the
CPG/FDAMA can apply simultaneously," the court declined to
assume that "its (re)adoption of the Colorado definition of
`compounding' compel[led] dismissal of any Counts" at that
time. <i></i><cite>Id. at 567</cite>. Of course, these determinations were
<i>voided</i> by the court's subsequent conclusion that the
definition of "compounding" &mdash; under Colorado law &mdash;
had no bearing upon Mr. Bader's case. <i>See</i> Aplee. App.,
Vol. IV, at 1256 ("With the benefit of hindsight and a full
trial record, the Court now recognizes that nearly all of the
briefing, discussion and analysis of `compounding' was an
unnecessary digression.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2300" name="fn2300">[fn23]</a></span> In the proceedings before the district court, Mr. Bader
challenged both the jury's $4.8 million forfeiture verdict and
the real property forfeiture of the College Pharmacy building,
which was used to facilitate the underlying crimes. However,
Mr. Bader's appellate arguments pertain exclusively to the $4.8
million monetary forfeiture.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2400" name="fn2400">[fn24]</a></span> Furthermore, the government contends that the second
claim concerning the counts of acquittal was not raised before
the district court. <i>See</i> Aplee. Br. at 53. Mr. Bader
does not deny this contention in his reply brief, and our
independent review of his district court filing supports the
government's contention. Therefore, even if his second claim
were not waived, Mr. Bader "could not prevail unless he could
successfully run the gauntlet created by our rigorous
plain-error standard of review." <i>McGehee</i>,
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1H5SKO003?jcsearch=672%20F.3d%20860&amp;summary=yes#jcite">672 F.3d at 866</a>. Mr. Bader does not even begin to shoulder his burden of
establishing that the district court erred &mdash; much less
clearly or obviously so &mdash; with respect to its treatment
of his counts of acquittal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2500" name="fn2500">[fn25]</a></span> For example, Mr. Bader's convictions under
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e) for discrete distributions of HGH on particular
dates (i.e., Counts Twelve through Fifteen, and Count Twenty)
trigger forfeiture under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976E2003?jcsearch=21%20usc%20853&amp;summary=yes#jcite">21 U.S.C. &sect; 853</a>. Under
<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)(3)&amp;summary=yes#jcite">&sect; 333(e)(3)</a>, "[a]ny conviction" under <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333&amp;summary=yes#jcite">&sect; 333</a> "shall be
considered a felony violation of the Controlled Substances Act
for the purposes of forfeiture." The Controlled Substances Act,
<i>see</i> <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976E2003?jcsearch=21%20usc%20853&amp;summary=yes#jcite">21 U.S.C. &sect; 853</a>, in turn man-dates that a
person who is convicted under the statute must forfeit "any
property constituting, or derived from, any proceeds the person
obtained, directly or indirectly, as the result of such
violation." <a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1976E2003?jcsearch=21%20U.S.C.%20%20853(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 853</a>(a)(1). As a controlled
substance felony offense, Mr. Bader's conviction for conspiracy
to distribute and to possess with the intent to distribute
testosterone cypionate (i.e., Count Nineteen) also triggers
forfeiture under &sect; 853(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn2600" name="fn2600">[fn26]</a></span> A panel of our Court previously has reached such a
conclusion. <i>See United States v. Lovett</i>, Nos. <cite>92-6401</cite>,
<cite>93-6070</cite>, [<a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/XQVMDJQNB5G0?jcsearch=1%20F.3d%201250&amp;summary=yes#jcite">1 F.3D 1250</a>], 1993 WL 298897, at *5 (10th Cir. July 26, 1993)
(holding that the district court "did not err in ordering . . .
forfeiture" where we had reversed two of the defendants
convictions and vacated four other counts, because we "did not
reverse or vacate his convictions" on three other counts upon
which the jury's forfeiture verdict may <i>also</i> have been
premised).
</p></div>
<!--BBLS DD 1706107404291-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HKTUQ003/history">Direct History (4)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HKTUQ003/analysis">Case Analysis (21)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HKTUQ003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
21
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Conviction Affirmed (In Part), Conviction Reversed (In Part), Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/document/X1Q6LC9L3B82">10-01263 (10th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Constitutional Law</div><div class='facetItemLabel'>Criminal Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/b10e2e1b81cfe142005c13f8c4941b8e/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "b10e2e1b81cfe142005c13f8c4941b8e";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYfb2826&previousPageId=&previousActivityInstanceId=ENTITYea2f5c&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:47:08-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HKTUQ003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYea2f5c&previousPageId=&previousActivityInstanceId=ENTITY282b10&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:47:05-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HKTUQ003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HKTUQ003";
$('#page_loader').show().spin();
JUDGE_IDS=["15878509","3028790","4127828"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
